

MicroRNA delivery through nanoparticles

Original

MicroRNA delivery through nanoparticles / Lee, S. W. L.; Paoletti, C.; Campisi, M.; Osaki, T.; Adriani, G.; Kamm, R. D.; Mattu, C.; Chiono, V.. - In: JOURNAL OF CONTROLLED RELEASE. - ISSN 0168-3659. - ELETTRONICO. - 313:(2019), pp. 80-95. [10.1016/j.jconrel.2019.10.007]

Availability:

This version is available at: 11583/2773672 since: 2019-12-16T10:24:35Z

Publisher:

Elsevier B.V.

Published

DOI:10.1016/j.jconrel.2019.10.007

Terms of use:

openAccess

This article is made available under terms and conditions as specified in the corresponding bibliographic description in the repository

Publisher copyright

Elsevier postprint/Author's Accepted Manuscript

© 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
<http://creativecommons.org/licenses/by-nc-nd/4.0/>. The final authenticated version is available online at:
<http://dx.doi.org/10.1016/j.jconrel.2019.10.007>

(Article begins on next page)



Review article

MicroRNA delivery through nanoparticles

Sharon Wei Ling Lee^{a,b,c,d,1}, Camilla Paoletti^{a,1}, Marco Campisi^a, Tatsuya Osaki^{e,g},
Giulia Adriani^{d,h}, Roger D. Kamm^{b,e,f}, Clara Mattu^{a,*,2}, Valeria Chiono^{a,2}

^a Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Corso Duca Degli Abruzzi 24, 10129 Torino, Italy

^b Singapore-MIT Alliance for Research & Technology (SMART), BioSystems and Micromechanics (BioSyM), Singapore, Singapore³

^c Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore³

^d Singapore Immunology Network (SIgN), Agency for Science, Technology, and Research, Singapore, Singapore³

^e Department of Mechanical Engineering, Massachusetts Institute of Technology, 500 Technology Square, Room NE47-321, Cambridge, MA, 02139, USA

^f Department of Biological Engineering, Massachusetts Institute of Technology, 500 Technology Square, Room NE47-321, Cambridge, MA, 02139, USA

^g Institute of Industrial Science, The University of Tokyo, Meguro-ku, Tokyo 153-8505, Japan³

^h Department of Biomedical Engineering, Faculty of Engineering, National University of Singapore, Singapore, Singapore

ARTICLE INFO

Keywords:

Nanoparticles
Physicochemical characterization
Biomaterials
MicroRNA delivery and release
Personalized medicine

ABSTRACT

MicroRNAs (miRNAs) are attracting a growing interest in the scientific community due to their central role in the etiology of major diseases. On the other hand, nanoparticle carriers offer unprecedented opportunities for cell specific controlled delivery of miRNAs for therapeutic purposes. This review critically discusses the use of nanoparticles for the delivery of miRNA-based therapeutics in the treatment of cancer and neurodegenerative disorders and for tissue regeneration. A fresh perspective is presented on the design and characterization of nanocarriers to accelerate translation from basic research to clinical application of miRNA-nanoparticles. Main challenges in the engineering of miRNA-loaded nanoparticles are discussed, and key application examples are highlighted to underline their therapeutic potential for effective and personalized medicine.

1. Introduction

MicroRNAs (miRNAs) are non-coding endogenous RNAs composed of short nucleotide sequences, 20–24 nucleotides, that act in the post-transcriptional regulation of gene expression [1]. As soon as miRNA activity was confirmed in humans [2,3], significant attention was generated on their clinical application, because of their impact on critical cellular activities, such as metabolism [4], differentiation/proliferation [5,6] and programmed cell death [6]. Several studies have described the influence of miRNAs on the onset and progression of diseases, including cancer [7–9], neurodegenerative disorders [10,11], cardiovascular diseases [12–14], and other pathologies [15–17]. Such studies have led to research that focused on identifying changes in miRNA expression between normal and diseased states, resulting in miRNAs being proposed as diagnostic markers or therapeutic targets [18–20]. However, despite the excitement generated by miRNAs, their efficacy is limited by poor targeting ability, short circulation time and off-target effects of naked miRNA-based agents. To overcome these barriers, miRNA-loaded nanoparticles (NPs) have been proposed [21–23], by virtue of NPs ability to shield the loaded agent from the external environment, thereby reducing inactivation or degradation, and enhancing circulation time and targeted accumulation [24]. Additionally, the use of miRNAs for therapeutic purpose carries distinctive advantages

over traditional gene therapy that involves the delivery of larger molecules, such as mRNAs, or DNA. Firstly, miRNAs have a broader range of therapeutic targets, since a single miRNA can simultaneously regulate a multitude of mRNAs. Furthermore, miRNAs in the form of miRNA inhibitor and miRNA mimic can regulate both the expression and the repression of multiple genes, while the activity of siRNAs and mRNAs is limited to repression or upregulation of one specific gene, respectively. miRNAs also have a small size, which may facilitate their encapsulation into NPs with high efficiency, their delivery into cells and their ability to act at the cytoplasmic level [25,26].

Herein, we discuss the preparation, characterization and application of NPs for delivering miRNA-based agents, which include miRNA mimics (miR mimics) or miRNA inhibitors/anti-miRNAs (miR inhibitors/anti-miRs) and focus on the advantages of NP-mediated methods as compared to naked miRNA delivery. Key examples of miRNA-loaded NPs for specific disease settings are presented, including their applications in tissue engineering (TE), cancer treatment, cancer immunotherapy and neurodegenerative disorders.

2. Physiological relevance of microRNAs (miRNAs)

MiRNAs are proposed to act primarily by binding to the 3' untranslated

* Corresponding authors.

E-mail address: Clara.mattu@polito.it (C. Mattu).

¹ These authors equally contributed as first authors.

² These authors equally contributed as last authors.

³ Present addresses.




Fig. 1. Endogenous production of miRNA and their mechanism of regulation of gene expression: (A) genes encoding for miRNA are transcribed and (B) miRNA precursor (pri-miRNA) form double-stranded structures. Pri-miRNAs are further transformed into (C) pre-miRNAs that are exported by Exportin into the cytoplasm to be (D) condensed into miRNA duplexes. (E) miRNA duplexes unwind to form the passenger and guide strands. The mature strand stays in the miRNA-induced silencing complex (miRISC), forming a (F) temporary asymmetric RISC assembly. Finally, miRNAs bind target mRNAs, thereby inducing (G) translational repression or (H) degradation of target mRNAs. This figure is adapted from <https://www.sigmaaldrich.com/life-science/functional-genomics-and-mai/mirna/learning-center/mirna-introduction.html>.

regions (UTRs) of messenger RNA (mRNA) without requiring perfect base pairing [27–29]. As such, one miRNA can simultaneously regulate several genes, while a single mRNA can be repressed by several miRNAs [25,26]. As shown in Fig. 1, miRNA formation begins in the nucleus with the DNA transcription of primary miRNA precursor (pri-miRNA) [30]. The transcribed pri-miRNAs are further processed to form ~70 nucleotide hairpin structures (pre-miRNAs), that are exported to the cytoplasm to be condensed into 20–24 nt double-stranded miRNA duplexes [31]. These duplexes then enter the miRNA-induced silencing complex (miRISC) where they unwind to form a mature strand and a passenger strand. The miRISC retains the mature strand and releases the passenger strand which is degraded [32]. miRISC binds target mRNAs, thereby inducing either interference with protein synthesis [33,34], or degradation of the target mRNA [35,36].

Depending on the target miRNA expression, miRNA therapy can take the form of: miRNA inhibition therapy [37,38], or miRNA replacement or reinforcement therapy (Fig. 2) [39,40]. In the former approach, an anti-miR or miRNA inhibitor is used, consisting of a single-stranded oligonucleotide with a complementary sequence to mature miRNA. In the latter approach, miR mimics that have an identical sequence as the endogenous mature miRNA are introduced into cells to provide an exogenous source of additional miRNAs.

3. Design criteria of nanoparticles (NPs) as efficient delivery vectors for miRNAs

Despite the progressively increasing knowledge of miRNA ability to mediate biological processes both *in vitro* and *in vivo*, critical hurdles related to miRNA delivery should be overcome to promote their clinical application [41,42]. Naked miRNAs are poorly taken up by cells due to their negative charge [43], undesired off-target [44] or on-target [45] effects, short half-life in systemic circulation [46,47], and limited stability in blood due to their rapid degradation or inactivation by nucleases that are abundantly present in the blood stream [48,49]. Herein, the main advantages and disadvantages of the different strategies to overcome the challenges of efficient miRNA delivery are discussed.

Both miR mimics and anti-miRs have been delivered *in vitro* using commercially available transfection agents, such as DharmaFECT™ and Lipofectamine™ [50–52], or by electroporation [53,54]. Alternatively, chemical modifications can be introduced to miRNAs to augment stability and allow carrier-free *in vivo* delivery of modified anti-miRs and miR mimics which are also known as antagomiRs [55] and agomiRs [56], respectively. For example, in the case of anti-miRs, *in vivo* silencing of endogenous miRNAs has been enhanced by integrating locked nucleic acids (LNA) or peptide nucleic acids (PNA), as reviewed elsewhere [57]. As an alternative to chemical modification, anti-miRs and miR mimics have been encapsulated into NPs. Due to their favorable transport properties, NPs have been reported to improve the *in vivo* delivery of miRNA agents; NPs protect their payload and enhance target specificity, [58] thus limiting adverse effects and improving therapeutic outcomes, as illustrated in Fig. 3 [59].

The main challenges in miRNA delivery with nanocarriers are related to their low encapsulation efficiency [60], and the need for cell targeting, as shown schematically in Table 1 [61,62]. Because of their high affinity with water, miRNAs quickly diffuse into the water phase when nanoprecipitation or emulsion-based preparation methods are used, resulting in low encapsulation efficiency [60]. NPs improve the tissue distribution and site-specific localization of miRNA. However, the degree of enhancement is generally poor. As such, numerous studies have focused on modifying the NP surface with ligands for specific receptors on target cells, thus facilitating NP uptake by receptor-mediated endocytosis and reducing the required dosage and side effects of treatment [21,63,64].

Moreover, colloidal stability of NPs in complex physiological media is demanded for cell-targeted delivery of miRNAs [65]. After administration, NPs should ideally circulate until they reach the desired site, and should be designed to undergo endosomal escape in order to guarantee the proper interaction between the miRNA and its intra-cellular target (for example by exploiting the proton sponge effect) [66,67]. However, circulation time depends on NP interactions with the biological microenvironment that could lead to their fast clearance. Specifically, once NPs are exposed to body fluids, their surface is covered by plasma proteins [68,69], resulting in masked surface ligands, non-specific uptake and reduced stability. There are




Fig. 2. (A) In a normal tissue state, expression of endogenous microRNAs (miRNAs) allows for gene regulation. In the treatment of certain diseases, (B) inhibition of specific endogenous miRNAs is achieved through miRNA inhibition therapy with anti-miRNAs (anti-miRs). (C) Alternatively, miRNA replacement therapy utilizes miR mimics to provide an exogenous source of additional miRNAs.

different factors affecting NP circulation half-life, sequestration by the mononuclear phagocyte system (MPS) and biodistribution, including surface charge and hydrophobicity, size and shape [24]. Previous studies showed that neutral particles are less subjected to opsonization than highly charged particles especially if positively charged (cationic) [70,71]. Similarly, high hydrophobicity is related to a higher likelihood of clearance, which can be reduced by modifying the surface with polyethylene glycol (PEG), or by surface-camouflaging strategies, resulting in enhanced circulation half-life [72–74].

Importantly, the disease setting crucially determines the physical and biological barriers that the NP must overcome in addition to the basic hurdles that already impede miRNA delivery [41]. Based on these considerations, different strategies can be developed to prepare NPs that can effectively deliver miRNA to the target cells.

4. Methods to prepare miRNA-loaded NPs

Various preparation techniques, such as single or double emulsions, nanoprecipitation, and interfacial polymerization, have been employed for the preparation of miRNA-loaded NPs. The selection of the most appropriate method is influenced by the constituent material and the desired surface characteristics [81]. Emulsion-based methods are the most commonly used to prepare miRNA-loaded NPs. These methods utilize high-speed homogenization or ultrasonication [82]. In the single-emulsion version, an oil-in-water (o/w) emulsion is formed by homogenizing or sonicating a polymer solution into an external, surfactant-containing, water phase. The double-emulsion technique, typically used to encapsulate hydrophilic payloads, utilizes two emulsification steps to obtain water-in-oil-in-water (w/o/w) or oil-in-water-in-oil (o/w/o) emulsions [81,83].

Emulsion methods have been used to prepare monomethoxy(polyethylene glycol)-poly(D,L-lactide-co-glycolide)-poly(L-lysine)-lactobionic acid (mPEG-PLGA-PLL-LA) [77], PLGA and poly(glycerol adipate-co- ω -pentadecalactone) (PGA-co-PDL) NPs for miRNA delivery [84]. For instance, miR-99a-loaded mPEG-PLGA-PLL-LA NPs have been obtained via the double emulsion method. For this purpose, miRNA is dissolved in water and subsequently dropped into a PLL-LA solution in dichloromethane, followed by sonication. The w/o/w emulsion was then dropped in water containing Pluronic-F68 and sonicated to obtain a w/o/w double emulsion. A reduction in the surface charge from 25 mV for blank NPs to 3 mV for miRNA-loaded NPs was taken as evidence of successful miRNA loading. The authors also demonstrate 80% of sustained payload release

at 132 h, suggesting extended duration for the interactions between miR-99a and target genes.

Polymer NPs can be formed via nanoprecipitation, by dropwise addition to water of a polymer solution in a water-miscible solvent, causing its rapid displacement [81,85,86]. For instance, miRNA-loaded PLGA/chitosan (PLGA/CS) NPs with 150–180 nm size have been prepared via the nanoprecipitation method by dropwise addition of PLGA solution into a water solution of CS and miR-34 s, in the presence of Poloxamer surfactant [75]. This method could achieve miR-34 entrapment efficiency (EE) between 50% and 95%, depending on the amount of miR-34 in the formulation, and controlled release up to 48 h.

Unconventional techniques, such as combination of click chemistry (CC) and controlled radical polymerization (CRP), electrospinning, and particle replication in non-wetting template (PRINT), can potentially be used to prepare miRNA-loaded NPs because of their versatility, ease of implementation and low cost. Although these techniques have not been used to prepare miRNA-loaded NPs, we advocate that they are advantageous methods, since harsh temperatures, extreme pH conditions or potentially-toxic solvents are not required. Combination of CC and CRP can allow the preparation of NPs with controlled size and improved stability, as shown with DNA-conjugated NPs [87–89], as well as *in vivo* active cell recognition, as demonstrated by Koo et al. with dibenzylcyclooctyne (DBCO)-modified liposomes that were able to bind the azide groups expressed on cancer cells [90]. PRINT is known to generate particles with precise structure through the use of elastomeric molds of predefined shape and size, into which a polymer solution containing the drug is poured. NPs obtained by PRINT have been used in mice studies to investigate specific tumour cell uptake [91], and to test the treatment of brain metastasis when loaded with docetaxel [92].

Finally, recent advances in microfluidics have enabled the synthesis of libraries of NPs by rapid mixing of droplet streams controlled by micro pumps into silicon or glass microchannels [93]. These micro-reactors provide homogeneous conditions for NP nucleation and growth, resulting in higher reproducibility [94]. The microfluidic technology has been used to engineer small interfering RNA-loaded NPs (siRNA-loaded NPs) [95], but to the best of our knowledge, no evidence of their use to prepare miRNA-loaded NPs has been reported.

5. Selection of the biomaterial for miRNA encapsulation

The choice of the biomaterial that constitutes the NP is of paramount




Fig. 3. Key challenges of miRNA delivery *in vivo*. The challenges of delivering naked miRNAs include hindered miRNA uptake by cells due to negatively charged groups of miRNAs, undesirable off-target or on-target effects, short miRNA half-life under physiological conditions and unfavorable immune response. NPs encapsulate miRNAs, thus shielding charge groups and allowing their uptake by cells. Functionalizing NPs with cell-specific ligands allows NPs to deliver miRNAs to specific cells, thus reducing off-target effects. NPs allow for controlled miRNA release, avoiding excessive activation of multiple gene targets. NPs also increase the half-life of miRNA *in vivo*, by protecting the payload from degradation. Finally, addition of a stealth coating around NPs prevents their clearance by the reticuloendothelial system (RES) and avoids unfavorable immune cell stimulation.

Table 1
Main general design criteria for miRNA-loaded nanoparticles (NPs).

NP requirements for <i>in vivo</i> delivery	Delivery challenges	Suggested improvements	Reference(s)
High encapsulation efficiency	miRNA water solubility and negative charge.	miRNA complexation with positively charged molecules prior to nanoprecipitation or emulsification.	[71,75,76,77]
Colloidal stability	Protein corona formation and possible aggregation.	Decoration of NP surface with anti-fouling molecules.	[72,73,74]
Cell targeting	miRNA off-target effects.	Surface functionalization of NPs with specific ligands for cell targeting.	[41,78,79]
Cargo release in cytoplasm	miRNA degradation in low pH of endosome.	Use of materials with proton-accepting groups, which enable miRNA complexation and protection from degradation (<i>i.e.</i> proton sponge effect).	[66,67]
Controlled and sustained release, and increased half-life	Fast NP degradation rate and burst-release.	Control degradation and/or trigger miRNA release with stimuli-responsive materials (<i>e.g.</i> containing pH-sensitive histidine-, tertiary amine-, and sulphonamide groups; or nitroimidazole or azobenzene groups for hypoxia-driven disassembly).	[80]

importance, as it dictates the choice of the preparation technique as well as the final properties and structure of the NP [96,97]. With the exciting advent of stimuli-responsive biomaterials, that change their properties upon modification of external conditions (including temperature or pH), multi-functional NPs have been developed for an expanding range of therapeutic applications (Table 2) [98,99].

5.1. Synthetic polymers

The use of synthetic polymer NPs for nucleic acid delivery has been extensively investigated, because of their efficient cargo release within the cell cytoplasm and their ease of manufacturing and functionalization with targeting molecules [41]. Among synthetic polymers, poly(ethylene imine)s (PEIs) [100,101], PLGA [75,76], poly(ϵ -caprolactone) (PCL) [102], and polyurethanes (PUs) [103,104] have been used for miRNA delivery.

PEI, both in linear and branched form, is a polycationic polymer. The PEI repeating unit consists of a secondary amine group and one ethylene spacer and is commercially available in different molecular weights, having different release efficiency and biocompatibility [105,106]. PEI chains are positively charged, depending on the protonation degree of secondary amines as a function of the pH. The positive charge allows electrostatic complexation with nucleic acids [107]. Due to its proton acceptor behavior, PEI exhibits weak-base buffering properties, reducing nuclease activity [108], and protecting nucleic acids from degradation within endosomal vesicles. As a proton acceptor, PEI also causes the “proton sponge effect”, leading to endosomal lysis and consequent release of nucleic acids into the cytoplasm [66,67,109].

PEI has been shown to deliver miR-145 and miR-33a, and allow the assessment of the *in vivo* anti-tumour activity of these miRNAs in a mouse model of colon carcinoma [101]. Local or systemic administration of PEI-miRNA complexes could result in reduced tumour growth compared to controls, indicating that such NPs represent a promising strategy for miRNA replacement therapy in cancer treatments [101]. PEI has also successfully delivered miR-145 *in vitro* to metastatic breast cancer cells [100], and *in vivo* in a xenograft colon cancer models [63].

However, while PEI NPs show efficient miRNA encapsulation and delivery, their high positive charge density and non-biodegradability can affect cell viability, thus limiting their use [108]. In this context, NPs that are surface-modified or based on blends of PEI and PEG have been proposed to reduce toxicity and improve biodistribution [110]. For instance, Zhang et al. have used branched PEI-PEG NPs to deliver miR-145 to prostate cancer [79]. The PEG chains were surface-modified with poly-arginine showing enhanced uptake in prostate cancer *in vivo*, reduction of tumour growth and increased survival.

Biocompatible and biodegradable synthetic polyesters, such as PLGA and PCL have also been investigated for nucleic acids delivery, because of their lower toxicity and biodegradability as compared to PEIs [111–113]. PLGA is a biocompatible and non-cytotoxic polymer, known to degrade by hydrolysis, generating lactic and glycolic acid monomers, which are metabolized through the Krebs cycle [111]. By varying the ratio between the constituent monomers, lactic and glycolic acid, the degradation rate of PLGA NPs can be tuned in the range from several months to years [111,114]. Low molecular weight polymers with higher glycolide content are more hydrophilic with a shorter degradation time. In contrast, PLGA NPs with higher lactic acid content have a hydrophobic nature and degrade more gradually.

MiRNA encapsulation is made difficult by the negative surface charge of PLGA NPs [115,116], which reduces complexation efficiency with the phosphate groups of miRNAs. This limitation can be overcome by using cationic compounds combined with PLGA. For instance, CS, a cationic polymer, has been shown to

promote the retention of miRNAs inside PLGA NPs [75]. Protamine sulfate (PS) coating of PLGA NPs has also been used to enhance complexation of miRNAs on the NP surface [76]. In another study, Wang et al. have generated PLGA-PEI NPs to co-deliver miR-542-3p and doxorubicin (DOX) in triple negative breast cancer cells [117]. PLGA-PEI NPs could be covalently grafted with hyaluronic acid (HA) to be specifically internalized by cancer cells, thus enhancing their cytotoxicity as assessed *in vitro* on breast cancer cells.

PCL has attracted high attention for the preparation of biocompatible NPs for nucleic acid delivery. NPs composed of PCL are promising for their high colloidal stability, quick cellular uptake, low toxicity *in vitro* and *in vivo*, and controlled release of their drug cargo. The degradation product of PCL is 6-hydroxyhexanoic acid, which is a natural metabolite in the human body [118]. Liu et al. have prepared PEG-peptide-PCL NPs by the double emulsion method to co-deliver miR-200c and docetaxel [102]. A gelatinases-cleavable peptide was selected to facilitate delivery after NPs internalization by tumour cells. In addition, spermidine has been used to complex with miR-200c during NP preparation, achieving about 85% transfection efficiency *in vitro*.

Among synthetic polymers, PU-based NPs have shown high biocompatibility combined with versatile physical and chemical properties [119]. Cationic PU-short branch PEI nanocomplexes have been developed by Chiou et al. as vehicles for miR-145 delivery to inhibit the stem cell niche in the brain tumour [103]. The authors demonstrate successful miR-145 transfection (nearly 90%) and efficient knockdown of miRNA targets, Sox2 and Oct4, *in vitro*. Intracranial injection of PU-PEI-miR-145 nanocomplexes could reduce tumour growth by synergizing with chemoradiotherapy. Furthermore, such nanocomplexes show a therapeutic effect on lung adenocarcinoma model [104], with decreased metastases, inhibited epithelial-to-mesenchymal transition (EMT) *in vitro*, increased survival and delayed tumour growth in mice [104].

5.2. Natural polymers

Among natural polymers, materials that can be obtained from animal or vegetal sources, CS and HA are promising carriers for nucleic acids [120–122]. CS is obtained from chitin and is non-cytotoxic, non-immunogenic, and highly biocompatible [123,124]. At acidic pH, the protonated amino groups of CS rapidly interact with opposite-charged molecules, such as siRNA or miRNA with high loading efficiency [22,125]. In spite of these advantages, CS NPs offer limited control over the delivery of nucleic acids because of their strong interaction with the loaded agent [126–128], which results in inefficient unpacking of the complex in the cytoplasm [127]. To overcome these drawbacks, hydrophobic moieties have been conjugated to CS to weaken the polymer/nucleic acid interaction and enhance cytoplasmic drug delivery. Lipid chains, bile acids or negatively charged polymers, such as PLGA, have also been combined with CS to facilitate miRNA release [129–131].

HA is a highly hydrophilic anionic natural polysaccharide, that can be recognized by HA receptors on cells [132,133]. By virtue of its chemical versatility, HA has been extensively used to prepare NPs for the delivery of cytostatic drugs, proteins, polynucleotides, immunomodulators and imaging agents. HA covalently grafted to cationic polymers or lipid molecules has been proposed to deliver polynucleotides. For example, HA chemically linked to PEI and PEG has been used to release miRNA and DOX [117,134]. HA has also been successfully used to modify the surface of cationic polynucleotide-loaded NPs [135]. However, although cationic polymers efficiently form complexes with nucleic acids due to charge interactions [129], their positive charge contributes to their uptake by the MPS with subsequent rapid elimination and toxicity [136]. For this purpose, several authors have proposed surface-modifications with HA to mask the positive charge of

Table 2
Applications and therapeutic effects of nanoparticles (NPs) for delivering microRNAs (miRNAs) and/or drugs in tissue engineering (TE) and cancer.

NPs	miRNAs	Application	Therapeutic effect	Stage	Ref
CS	agomir-199	Tibia regeneration	Osteogenic differentiation of MSCs and bone regeneration	Pre-clinical Bone defects on Sprague–Dawley rats	[56]
Hyaluronan sulfate	miR-21	Myocardial infarction	Reduced inflammation and reduced cardiac fibrosis	Pre-clinical Myocardial infarction in C57BL/6 mice	[159]
PEI-PLGA	miRNAs targeting COX1 & COX2	Flexor tendon adhesions	Reduced inflammation and support for tendon healing	Pre-clinical Tendon injury in chicken	[160]
PLGA	miR-26a	Calvarian bone regeneration	Increased osteoblastic activity	Pre-clinical Bone defect in C57BL/6 mice	[161]
Polyketal	miR-106b, miR-148b and miR-204	Myocardial infarction	Improved cardiac function and reduced infarct size	Pre-clinical Myocardial infarction in C57BL/6 mice	[162]
Fe ₃ O ₄ -PEI	Let-7a	Glioblastoma	PI3K and RAS downregulation	In vivo proof of concept (sub cutaneous breast cancer in nu/nu mice)	[144]
Gold	miR-182	Brain cancer	Reduced tumour burden and increased survival	Pre-clinical Intra-cranial tumours on SCID mice	[163]
Gold	miR-145	Breast cancer, prostate cancer	miR-145 expression recovery	In vitro	[78]
HA-CS	miR-34a and doxorubicin (DOX)	Triple negative breast cancer	Increased cell sensitization to DOX	In vitro	[117]
Liposomes	miR-101 and DOX	Hepatic carcinoma	Reduced tumour growth	Pre-clinical Intra-cranial tumours in C57BL/6 mice	[23]
Liposomes	Anti-miR-21	Glioblastoma	Inhibition of miR-21 expression	Pre-clinical Intra-cranial tumours in C57BL/6 mice	[164]
PEG-lipids	miR-122	Hepatic carcinoma	Reduced tumour growth	In vivo proof of concept Flank model of HCC in nude mice	[158]
PCL-PEG	miR-200c and docetaxel	Gastric cancer	Tumour growth inhibition	In vivo proof of concept Flank model in Balb/C mice	[102]
PEI-PEG	miR-145	Prostate cancer	Tumour growth inhibition	Pre-clinical Intra-peritoneal tumour in nude mice	[79]
PEI	miR-145 and miR-33a	Colon carcinoma	Reduced tumour growth	In vivo proof of concept subcutaneous tumour in nude mice	[101]
PEI	miR-145	Metastatic breast cancer	Reduced cell proliferation <i>in vitro</i>	In vitro	[100]
PLGA	miR-99a	Hepatic carcinoma	Tumour growth inhibition	In vivo proof of concept subcutaneous tumour in nude mice	[77]
PLGA-PEG	miR-7 and paclitaxel (PTX)	Ovarian cancer	Increased cancer cell apoptosis and sensitization to PTX <i>in vitro</i>	In vivo proof of concept subcutaneous tumour in nude mice	[165]
PLGA-PEI-HA	miR-145	Colon carcinoma	Tumour growth inhibition	In vivo proof of concept subcutaneous tumour in nude mice	[63]
PU-PEI	miR-145	Lung tumour	Reduced tumour growth and prolonged survival	Pre-clinical Intra-bronchial tumours in nude mice	[103,104]
PU-PEI	miR-145	Brain tumour	Reduced tumour growth and prolonged survival	Pre-clinical Intra-cranial tumours in nude mice	[104]
Silica	Anti-miR221	Glioma	Increased cancer cell apoptosis <i>in vitro</i>	Pre-clinical Intra-cranial tumours in nude mice	[146]
Silica	miR-34a	Neuroblastoma	Tumour growth delay and apoptosis and reduced vascularization	In vitro	[147]

cationic NPs, lipid complexes or liposomes [135]. For instance, HA has been electrostatically attached to the surface of positively charged liposomes [137,138] and calcium phosphate NPs [139], as well as chemically bound to lipids on the NP surface. Liang et al. have used HA-NPs loaded with miR-145 to target colon cancer cells through their overexpressed CD44 receptors. Real-time qPCR and western blot analyses revealed enhanced accumulation and reduced tumour growth [63], suggesting the potential therapeutic success of utilizing such NPs in the clinic.

5.3. Inorganic NPs

Due to their biocompatibility, controllable size and morphology, several inorganic materials have been proposed in nanomedicine, including gold, calcium phosphate, silica and iron oxides [140,141]. Firstly, iron oxide-based NPs have been proposed for imaging purposes, as contrast agents for magnetic resonance imaging (MRI), in thermal therapy, as well as in drug and gene delivery. The combination of magnetic NPs with cationic compounds is needed to achieve high miRNA encapsulation [142]. Streptavidin-coated magnetite (Fe₃O₄)-based NPs have been modified with biotin-bound miR-335/PEI complexes to deliver the miRNA cargo to human mesenchymal stem cells (hMSCs), achieving enhanced target gene knock-down as compared to a PEI-miR strategy [143]. Yin et al. have used zinc-doped Fe₃O₄ NPs to deliver let-7a miRNA to glioblastoma cells by magnetofection [144]. Loading of let-7a miRNA into NPs has been achieved *via* a layer-by-layer approach, using branched PEI as polycation. These complexes showed high cellular uptake (at nearly 98%) and downregulation of the let-7a targets, PI3K and RAS.

Silica NPs and mesoporous silica NPs (MSPs) are silica-based nanostructures which possess high biocompatibility and stability [145]. For these reasons, MSPs have received great attention in clinical applications. MSPs have been used to co-deliver anti-miR-221 and Temozolomide (TMZ) to treat drug-resistant glioma cells [146]. Silica NPs carrying a tumour suppressor miRNA miR-34a have been developed by Tivnan et al. to specifically inhibit neuroblastoma growth [147]. GD2-antibody could further be conjugated on the NP surface to enhance specific targeting, delaying tumour growth, enhancing apoptosis and reducing vascularization *in vivo*.

Calcium phosphate (CaP) NPs are inexpensive, nontoxic, bioresorbable and easily synthesized nanocarriers. They have been widely used as gene carriers for 40 years, using DNA-CaP co-precipitation as an efficient method to introduce nucleic acids into cells; they remain stable in the endosomal compartment and are rapidly degraded in the mildly acidic lysosome environment, causing the vesicle to burst, releasing their content in the cytoplasm [148]. Banik et al. have shown that large molecular weight gene therapeutics, such as plasmid DNA can successfully interact with CaP-NPs in a spontaneous and cooperative manner, without NP intercalation with DNA base pairs [148]. However, miRNAs might have poor interaction because of low spatial charge density. Accordingly, long-chain miRNAs (lc-miRNAs) have been developed to enhance encapsulation efficiencies into PEI-CaPNPs [149]. Lc-miRNAs have been prepared by adding thiol groups on both the 3' and the 5' miRNA end, thus obtaining longer chains with higher encapsulation efficiency.

Gold NPs (Au-NPs) have been used in drug delivery by virtue of their biocompatibility, ease of functionalization, and tunable size and shape [150–152]. The surface of Au-NPs is typically functionalized with thiol or amino groups to enable miRNA entrapment. Ghosh et al. have developed a non-toxic gold-based formulation to obtain excellent miRNA cellular uptake through endocytosis and intracellular delivery [153]. This formulation was based on miRNA/ Au-NPs-S-PEG, with a ratio of 1-10-0.5, respectively. Cystamine functionalization of Au NPs can also be used for miRNA complexation, whereas PEG can prevent NP aggregation and miRNA degradation. Ekin et al. have used Au-NPs to deliver and recover the expression of miR-145 (a tumour suppressor gene) into prostate and breast cancer cells, where miR-145 is usually downregulated [78].

5.4. Lipid-based NPs

Lipids are the main components of the cell membrane, thus making lipid-based NPs (LNPs) capable of interacting with the membrane, promoting cellular uptake of their contents. LNPs are composed of a lipid bilayer that contains the miRNA in the aqueous core or, in the case of multi-lamellar liposomes, between lipid bilayers [154]. Typically, miRNA-loaded LNPs are made with a mixture of cationic lipids, neutral lipids and PEG [155]. Spontaneous electrostatic interaction between cationic lipids and negatively charged miRNA results in an efficient condensation of miRNAs and in their protection from enzymatic degradation. Also, the positive charge facilitates the interaction with the opposite-charged cellular membrane [155]. However, the use of cationic lipids is commonly associated with cell toxicity, as they can disrupt cell membrane integrity, induce cytoplasm vacuolization and




Fig. 4. microRNA (miRNA) therapeutic approaches in tissue engineering (TE). (A) Different miRNA-based therapeutic strategies for cardiac repair and regeneration after injury. miRNAs can (a) augment the regenerative capacity of adult cardiac progenitor cells, (b) reprogram human fibroblasts into cardiomyocytes *in vivo*, and (c) directly reprogram human fibroblasts into cardiomyocytes *in vivo*, and (d) guide gene expression associated with cardiac repair. This figure was created with BioRender. (B) miRNA-based therapy to regenerate bone defects, using a cell-free 3D scaffold loaded with miR-26a-containing PLGA microspheres. Image reproduced with permission from Zhang, X. et al., Nature communications, 7 p.10376 (2016) <http://creativecommons.org/licenses/by/4.0/>.

reduce cell activity [156]. Furthermore, the presence of cationic lipids can result in the interaction with negatively charged serum proteins, thus inducing aggregate formation, which are subsequently eliminated by the liver and the spleen. For these reasons, several strategies to reduce the cationic charge have been attempted. For instance, combination with neutral lipids, such as cholesterol (Chol), dioleoylphosphatidyl ethanolamine (DOPE) and phosphatidylcholine (PC), known as “helper lipids”, has been proposed to enhance stability and reduce toxicity of LNPs [157]. PEG modifications on the LNP surface have also been implemented to increase their half-life. PEGylated cationic/neutral LNPs have been used for the systemic delivery of liver-specific tumour suppressor miR-122 in hepatocellular carcinoma (HCC), achieving ~ 50% decreased growth after 30 days [158].

6. Therapeutic application of miRNA-based nanomedicine

6.1. miRNA-based nanomedicine in tissue engineering (TE)

MiRNAs are potent therapeutics for TE applications. In this context, miRNA-activated scaffolds can be prepared for tissue-specific miRNA replacement, or modulation (Fig. 4). Here, we report the recent results with miRNA in TE, focusing mostly on cardiac and bone regeneration.

Myocardial infarction (MI), a leading cause of death, consists in the irreversible loss of cardiomyocytes, cardiac ECM degradation and the formation of a fibrotic scar. [166] The discovery that miRNA treatment can induce cardiomyocyte proliferation and the direct reprogramming of fibroblasts into cardiomyocytes have raised the interest in using miRNAs as potential therapeutics in MI, as illustrated in Fig. 4A [167,168]. In spite of the excitement raised by these findings, the lack of suitable delivery vehicles for miRNAs have limited their practical application. Recently, Di Mauro et al. have generated CaP-NPs which successfully encapsulated and delivered miR-133 or miR-39-3p into murine cardiac cells without altering their biological function [169]. When administered *in vivo*, via retro-orbital injection, miRNA-encapsulated CaP-NPs accumulated in the left cardiac ventricle and in the liver, spleen and kidney. This non-specific uptake suggests that surface-modification of NPs for specific tissue targeting can improve the efficacy of miRNA-loaded NPs. Yang et al. have generated polyketal (PK3) NPs loaded with a combination of three miRNAs (miR-106b, miR-148b and miR-204), targeting Nox2, a ROS intermediate, with increased expression after MI [162]. Potentially, the inhibition of Nox2 expression by local treatment with NPs improved cardiac function and reduced infarct size in mouse models. Bejerano et al. also showed tissue remodeling post-MI through the delivery of miR-21 assembled into hyaluronan-sulfate (HAS) NPs [159]. After MI, prolonged macrophage recruitment to the infarct area could result in persistent inflammation and delayed tissue repair, thus inducing further cardiac damage. Also, miR-21 upregulation in peritoneal macrophages has been previously shown to promote inflammation resolution [170]. HAS-mediated delivery of miR-21 *in vivo* could elicit the natural reparative ability of macrophages, thus reducing cardiac fibrosis and cell apoptosis.

Several studies have elucidated the role of miRNAs in bone remodeling, by controlling osteoblast differentiation and inhibition through the regulation of different signaling pathways [171]. Zhao et al. have used CS-based NPs to deliver anti-miR-138 to bone marrow mesenchymal stem cells (BMSCs) to promote osteogenic differentiation [172]. Anti-miR-138 could regulate the ERK1/2 pathway, inducing osteoblast differentiation. Wang et al. have engineered miR-21-loaded HA/CS NPs (miR-21-HA/CS NPs) that could coat cell culture plates to induce osteogenic differentiation of BMSCs [173]. miR-21 has been selected because it downregulates SOX2 expression, thereby inducing the differentiation of hMSCs towards osteogenic lineages. After BMSC transfection with miR-21-HA/CS NPs, osteogenic-related genes could be upregulated compared to controls, including Collagen type I alpha1 (COL1), osteopontin (OPN), Runt-related transcription factor 2 (RUNX2), and osteocalcin (OCN). Moreover, after 14 days of culture with miR-21-HA/CS NPs, BMSCs that were subsequently cultured in an osteogenic differentiation medium could display significantly higher ability for ECM mineralization, as suggested by a higher calcium accumulation compared to controls.

As TE often requires the presence of three-dimensional (3D) constructs to favour and support new tissue ingrowth, recent approaches combining NPs with injectable hydrogels or scaffolds have also been exploited. For instance, Zhang et al. have proposed a two-stage miRNA delivery strategy to improve controlled release and transfection efficiency of miR-26a for calvarial bone regeneration (Fig. 4B) [161]. This strategy relies on the encapsulation of polyplexes carrying miRNAs into PLGA microspheres and their subsequent immobilization onto poly(L-lactic acid) (PLLA) scaffolds. This two-stage miRNA delivery could regenerate bone defects in mice by activating the osteoblastic activity of endogenous stem cells.

CS hydrochloride NPs loaded with agomiR-199-5p have been used to induce

hMSC osteogenic differentiation *in vitro* through the regulation of the HIF pathway [56]. NPs could allow sustained agomiR-199-5p delivery *in vitro* for at least 21 days. Here, agomiR-loaded NPs were encapsulated into a fibrin gel and the scaffolds were implanted within a tibia bone defect in rats, allowing successful *in situ* bone tissue regeneration. In another study, Zhou et al. demonstrate a local sustained gene delivery system by using PEI-modified PLGA-NPs embedded into HA hydrogel, to deliver an engineered miRNA plasmid which targets cyclooxygenase COX-1 and COX-2 to reduce flexor tendon adhesions [160]. Administration of miRNA by PLGA NPs in hydrogel could prevent tendon adhesions by decreasing inflammatory response by directly downregulating COX-1 and COX-2.

6.2. miRNA-based nanomedicine in cancer

In cancer treatment, miRNA-based therapy can follow two strategies: (i) miRNA inhibition and (ii) miRNA replacement (Fig. 5) [174]. The first approach provides specific anti-miR oligonucleotides (AMOs) that inhibit tumour-promoting miRNAs (oncomiRs), such as miR-519a and miR-32 [175,176]. The latter strategy aims at introducing exogenous miRNAs (miR mimics) known to promote tumour suppression, such as miR-34a and let-7b [177,178]. However, in spite of the evidence of potentiated anti-cancer toxicity of combinational treatments based on anti-cancer drugs and miRNAs, clinical application is limited by practical hurdles. Preclinical trials have highlighted the difficulty of delivering naked miRNAs to tumours and the need for more efficient delivery systems [179,180].

Numerous authors have shown that chemotherapeutics and miRNAs can be encapsulated within NPs, representing an effective strategy to achieve potentiated cytotoxicity both *in vitro* and *in vivo*. For instance, miRNA-mediated regulation of the p53 network or the extracellular signal-regulated kinase (ERK) pathway has been used in synergy with cytotoxic drugs, such as DOX and Paclitaxel (PTX) [165,181]. Deng et al. have designed CS/HA NPs, exploiting the positive charges of CS to form complexes with miR-34, a regulator of the p53 pathway. DOX was co-encapsulated with miR-34 into CS/HA NPs, showing enhanced efficacy against triple negative breast cancer cells *in vitro*, as miR-34 restored the normal p53 pathway, sensitizing the cells to DOX chemotherapy [181]. Recently, nano-sized liposomes have also been prepared encapsulating DOX in combination with miR-101, a tumour-suppressive miRNA that is downregulated in HCC [182]. The effect of co-delivery could inhibit the growth of malignant HCC cells, both *in vitro* and *in vivo*, due to the synergistic effect of both agents [23].

Cui et al. demonstrate that the co-encapsulation of PTX and miR-7 into mPEG-PLGA-PLL-LA NPs [165]. miRNA-7 suppresses the EGFR/ERK pathway, which is known to drive cell proliferation and resistance to PTX [122,183]. Their developed NPs could enhance PTX release and improve miRNA efficiency, resulting in increased apoptosis of ovarian cancer cells and reduced resistance to PTX [165]. Costa and colleagues demonstrate the preferential accumulation within brain tissue of liposomal NPs that were conjugated with chlorotoxin (CTX), a glioma-specific peptide marker. CTX-NPs could efficiently deliver anti-miR-21 oligonucleotides, with no signs of systemic immunogenicity [164].

Studies on lung adenocarcinoma (LAC) have shown the presence of a small subset of cancer stem cells (CSCs) with altered miRNA expression [184]. miR-145 loaded into PU-PEI NPs showed beneficial effect on LAC metastases through the inhibition of EMT processes and improved sensitization to chemoradiotherapies, prolonging survival of mice. Abnormal expression of miRNAs has also been found in malignant brain tumours. For instance, inhibition of miRNA-21 has been used in GBM treatment to rescue tumour suppressor genes, such as PTEN and PDCD4, while miRNA-182 has been associated with favorable prognosis because of its role as a regulator of apoptosis, growth, and differentiation [185–187]. Anti-miR-21 NPs co-encapsulating DOX have demonstrated enhanced cell apoptosis and reduced tumour growth in brain tumour models [64]. Kouri et al. demonstrate gold NPs covalently functionalized with miR-182 that can selectively deliver miR-182 to brain tumours, reducing tumour size and increasing survival [163]. These studies demonstrate the extensive potential of miRNA-loaded NPs in cancer treatments.

7. Frontiers in miRNA-based therapies

7.1. Cancer immunotherapy

MiRNAs play a significant role in immune system modulation [188]. As a result, inhibiting or upregulating specific miRNAs can potentially modulate the immune response to tumours, for example by controlling macrophage polarization or by regulating their activities in the tumour micro-environment (TME) [189,190]. For instance, upregulation of specific miRNAs, such as let-7c [191,192], and miR-146a [193,194] has been shown to drive




Fig. 5. (A) Roles of microRNAs (miRNAs) in cancer. Depending on the target gene, miRNAs suppress or stimulate cancer-related genes. Image modified from Oliveto, S. et al., World journal of biological chemistry, 8 (1), p.45 (2017). (B) Therapeutic approach using miRNA-loaded polymer NPs circulating in the tumour microenvironment. Images (A) and (B) were created with BioRender.






Fig. 6. NPs can be applied in cancer immunotherapy to i) enhance the activity of T cells, ii) induce macrophage reprogramming towards the tumoricidal M1 phenotype, iii) target immune cells and exploit their tumour infiltration ability to penetrate inside the tumour mass, where release can be triggered by either internal or external stimuli. Image modified with permission from Gun, S. Y. et al., Redox biology, p.101174 (2019) (published under Creative Commons attribution Licence CC-BY).

A MicroRNAs therapy



B Surface charge



Negatively charged NPs

Positively charged NPs

C Neuronal targeting ligand

- (i) RVG-derived 29-amino-acid (ii) Tet1 12-amino-acid





Fig. 7. (A) Representative potential microRNA-therapies for treating neurodegenerative diseases. Targeted NPs release miRNA to neurons by: (B) surface charge (reproduced with permission from Dante, S. et al., ACS Nano 11, 6630–6640 (2017)), or (C) surface functionalization with specific neuronal binding ligand such as (i) RVG-derived 29-amino-acid and (ii) Tet1, 12-amino-acid (reproduced with permission Kumar, P. et al. ACS Nano 2016, 10, 8 7926–7933 and Kwon, E. J. et al., Biomaterials 31, 2417–2424 (2010), respectively).

immunosuppressive and pro-tumour activity of (pro-tumour) “M2”-type tumour-associated macrophages (TAMs). In contrast, (anti-tumour) “M1”-type macrophages, characterized by tumoricidal activity, can be induced by increased expression of a.o. miR-125b [192,195], and miR-155 [196–198]. As immunomodulation is often constrained by poor specificity, NP-based specific delivery of immunomodulatory agents has the potential to improve on-target delivery while minimizing off-target effects (Fig. 6) [199]. Although numerous studies have demonstrated the anti-tumour efficacy of NP-based immunomodulation, targeting macrophages, T cells, and dendritic cells (DCs) [200,201], there is a startling lack of studies on immunomodulation through miRNA-loaded NPs. Importantly, the design of miRNA-based NP platforms for immunomodulation may build upon existing RNA-based NP technologies or immune system targeting strategies, briefly summarized below [8,202–204].

Researchers have used monocytes/macrophages as enablers of NP-based anti-cancer therapy, by virtue of their ability to naturally home to tumours. Choi et al. show that macrophages that phagocytized gold nanoshells (Au-NS) can accumulate into breast tumour spheroids, resulting in cancer cell death through photo-induced ablation [205,206]. Anselmo et al. and Doshi et al. have attached a therapeutic cargo to monocytes in the form of a “cellular backpack” and demonstrate that monocyte-associated “backpacks” could accumulate to greater degree in inflamed organs, as compared to a “free backpacks” [207,208]. Alternatively, Song et al. demonstrate the TAM-specific delivery of siRNA targeted against vascular endothelial growth factor (VEGF) and placental growth factor (PIGF), that support the pro-tumour activity of TAMs [209]. Mice being administered with siRNA-loaded NPs showed decreased TAM accumulation in the tumour microenvironment and striking reductions in tumour growth compared to control mice.

Similarly, T cells, which display cytotoxic activity against tumour cells, can be exploited to facilitate intratumoral delivery of NPs [210,211]. For example, Siriwon et al. show that CAR T cells can effectively deliver and release an antagonist against T cell activity deep within the tumour microenvironment, thus supporting effector T cell cytotoxicity [212]. NPs can also be used to deliver cytotoxic T lymphocyte molecule-4 (CTLA-4) siRNA into tumour-infiltrating T

cells (TILs), to increase the proliferation and the anti-tumour activity of effector T cells [213]. Smith et al. have utilized NPs to deliver leukemia-specific CAR genes into T cells, achieving long term disease remission [214]. This strategy could potentially be used to achieve a sufficient pool of therapeutic T cells to elicit “on-demand” cancer immunity [214].

NPs-based immunotherapy can also be achieved by targeting dendritic cells (DCs). DCs present epitopes of tumour-associated antigens (TAAs) to T cells, activating T cells for their attack of TAA-presenting tumour cells [215]. Self-assembled DNA–RNA nanocapsules have been developed to that deliver tumour neoantigens to DCs, increasing the CD8⁺ T cells and reducing the growth of colorectal tumours [8]. Warashina et al. have developed a lipid NP for DC-specific delivery of siRNA against a suppressor of cytokine signaling 1 (SOCS1). Treated DCs displayed a marked increase in cytokine production with consequent reduction of tumour growth *in vivo* [216]. Kranz et al. have further exploited the antiviral defence mechanisms of DCs, using DC-targeting RNA-lipoplexes to trigger the release of pro-inflammatory interferon-α [217].

7.2. Neurodegenerative disorders

Neurodegenerative disorders, such as Parkinson's disease (PD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Huntington's disease (HD), are characterized by, among other features, the progressive loss of neuronal synapses, leading to neuronal death. Recent studies have reported that abnormal miRNA expression contributes to the degradation of neurons [218], suggesting that neurodegenerative diseases can be classified as an RNA disorder [219]. miRNA-loaded NPs that regulate RNA transcripts may thus represent a form of novel therapeutics for treating neurodegenerative diseases (Fig. 7) [220].

Comparative studies of miRNA profiles in post-mortem brain tissue from PD patients and healthy controls have shown altered miRNA levels in PD patients. For instance, miR-7, miR-153, and miR-433 drive the over expression of α-synuclein, which has been associated with aberrant soluble oligomeric conformations in *in vitro* experiments [221,222]. Dysregulation of miR-34 has been

associated with the pathogenesis of PD along with altered mitochondria activity and oxidative stress [223]. In addition, several studies show reduced expression of miR-133 in PD patients, which regulates dopaminergic neuron development, differentiation and maturation [224]. miR-133 also further regulates Pitx3, a transcription factor involved in dopaminergic neuron differentiation [225].

Additionally, many miRNAs are abnormally regulated in the brains of AD patients. For instance, decreased expressions of miR-29, miR-189, and miR-9 are found in the AD brain, as evidenced by genome-sequencing and miRNA profiling. Decreased expressions of miR-298, miR-328 and miR-195 have been found in AD mouse models [226,227]. Recent studies have shown the relationship between miRNA dysregulation and extracellular amyloid β plaque (A β) production and aggregation which gives rise to neuro-degeneration [228]. For example, decreased expression of miR-107 may contribute toward faster disease progression by regulating beta-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) [229]. miR-106a and miR-520c have been found to suppress the expression of APP *in vitro* [230]. miR-17 and miR-20a, along with miR-147, miR-153, miR-644, and miR-655 as well as miR-323-3p, have been found to directly target APP [231]. Additional studies have identified dysregulated miRNAs that contribute to AD pathogenesis through atypical regulation of numerous proteins, which is involved in disease progression. Downregulated miR-103 or miR-107 expression can also lead to increased cofilin 1 (CFL1) levels in AD brains, which may associate with the formation of intracellular Hirano bodies [232]. Other studies show that decreased expressions of miR-9, miR-137, miR-181c, and miR-29b-1 in AD brain can upregulate serine palmitoyltransferase (SPT), long chain subunit 1 (SPTLC1) and 2 (SPTLC2), which are the rate-limiting enzymes in the synthesis of ceramides [233].

The dysregulation of miRNA also plays an essential role in other neurodegenerative diseases. Many studies have identified ALS-relevant transcripts and pathways that are targeted by dysregulated miRNAs. For instance, miR-132 regulates acetylcholinesterase and polypyrimidine tract binding protein 2 (PTBP2), which influences alternative splicing of tau in ALS [234]. Wang et al. showed that miR-219 and miRNA-338 downregulation is observed in murine CNS, regulating oligodendrocyte differentiation and myelination [235]. Several miRNAs may also play a role in HD, particularly by targeting the Huntingtin gene (Htt). Sinha et al. show that miR-125b, miR-214, miR-150, miR-146a have the potential to reduce Htt aggregates [236]. The encapsulation of these miRNA in NPs may further represent a feasible strategy for more efficient delivery, thus contributing to improved therapeutic outcomes.

To date, delivery of miRNAs to the brain and to the spinal cord mainly relies on recombinant adeno-associated virus (rAAV) [237]. Miyazaki et al. showed that miR-196a delivery using AAV vector could enhance the decay of mRNA androgen receptor by silencing Elav-like family member 2 (CELF2) in mice [238]. They found that the early delivery of miR-196a by an AAV vector could ameliorate the spinal and bulbar muscular atrophy phenotype in mice. Another study showed that miR-132 delivery using AAV9 vector could recover motor function, thus regulating muscle locomotion as well as survival rate of HD model mice [239].

As AAV vectors have a limited capacity for encapsulation (4.5–5 kb) due to size limitations, non-viral vectors may substantially increase miRNA delivery efficiency to the brain, improving neurodegenerative disease treatment. Drug delivery to the brain mediated by NPs can also allow blood-brain barrier (BBB) crossing and selective targeting of neurons. For example, heat generation from iron oxide NPs has been shown to enhance BBB bypass of NPs [240]. Dante et al. showed that negatively charged (–COOH) NPs could effectively localize at the membrane of neurons and influence neural excitability [241,242]. Ligand-based targeting has been also considered for the improved delivery of NPs to brain and neurons. Kumar et al. reported that a short peptide-derived rabies virus glycoprotein (RVG) localize on neuronal cells *in vitro* through specific binding to the acetylcholine receptor [243]. Kwon et al. proposed a non-viral delivery vehicle to adult neural stem cells using a 12-amino-acid, Tet1, which could bind specifically to neuronal cells [244]. Therefore, NPs represent potential therapeutic tools in neurodegenerative disorders by virtue of their ability to deliver miRNA treatments to deeper regions of the brain.

8. Conclusions

As important regulators of cell behavior in normal and pathological conditions, miRNAs hold immense potential for clinical applications, ranging from cancer therapy to TE approaches for the treatment of bone and cardiac defects, to neurological disorders, as described in the above paragraphs [3]. Moreover, because miRNAs inhibit/promote the expression of a multitude of genes

compared with mRNA and siRNA, miRNA therapy potentially carries distinct advantages for disease treatment and regenerative medicine [25,26]. Efficient and safe delivery of miRNAs is of paramount importance for their exploitation in the clinics, as naked miRNAs are susceptible to rapid degradation and traditional transfection reagents are not suitable for in-human applications [8].

Encapsulation of miRNAs into NPs can overcome these delivery challenges, resulting in enhanced targeting efficacy and reduced off-target effects of the encapsulated payload. Importantly, the design of NPs with genetic cargo has primarily focused on siRNA, DNA, plasmids or oligonucleotides, and only few have detailed work with miRNA. In this work, we discussed the advantages of nanomedicines for miRNA delivery, reviewed the recent applications of NPs and miRNAs carriers, and highlighted potential new fields of use, which can benefit from miRNA-based therapies. The development of miRNA-loaded NPs is nascent and, often, authors describe methods for preparing NPs for miRNA delivery while referring to previous protocols, which are originally developed for drugs or other types of RNA or DNA cargo. Few studies present a thorough comparison between miRNA-loaded NPs and NPs with other RNA (for example siRNA-loaded NPs) [245]. Even so, these comparative studies only investigated the physico-chemical properties of the NPs or their uptake by cells *in vitro* and it remains to be validated if these findings are also relevant *in vivo*. Indeed, as crucial biochemical differences exist between miRNAs and other nucleic acids, we should be cautious to extrapolate or predict outcomes for miRNA-loaded NPs based on the findings of other DNA/RNA-associated NPs. Nonetheless, our understanding of miRNA-loaded NPs is only beginning, and the future holds several therapeutic possibilities for miRNA-loaded NPs.

Acknowledgements

This work was supported by the MIT-POLITO grant BIOMODE – Compagnia di San Paolo (M.C., R.K., V.C.), the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (BIORECAR, grant agreement No. 772168, V.C.), National Research Foundation, Prime Minister's Office, Singapore, under its CREATE program for the Singapore-MIT Alliance for Research and Technology BioSystems and Micromechanics IRG (S.L., R.K.), a core grant to Singapore Immunology Network (SIgN) from Agency for Science, Technology and Research (A*STAR) (G.A.), National Science Foundation, Science and Technology Center on Emergent Behaviors of Integrated Cellular Systems (CBET-0939511) (T.O., R.K.) and from the US National Cancer Institute (U01 CA214381-01) (R.K.). C.M. acknowledges funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 658665. M.C. and C.P. acknowledge support from the joint “Doctorate of Bioengineering and Medical-Surgical Sciences” of University of Turin and Politecnico di Torino.

References

- [1] M. Wery, M. Kwapisz, A. Morillon, Noncoding RNAs in gene regulation, Wiley Interdiscip. Rev. Syst. Biol. Med. 3 (2011) 728–738, <https://doi.org/10.1002/wsbm.148>.
- [2] G.A. Calin, C.D. Dumitru, M. Shimizu, R. Bichi, S. Zupo, E. Noch, H. Aldler, S. Rattan, M. Keating, K. Rai, L. Rassenti, T. Kipps, M. Negrini, F. Bullrich, C.M. Croce, Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia, Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 15524–15529, <https://doi.org/10.1073/pnas.242606799>.
- [3] J. Li, Z. Zhang, miRNA regulatory variation in human evolution, Trends Genet. 29 (2013) 116–124, <https://doi.org/10.1016/j.tig.2012.10.008>.
- [4] H. Zhu, N. Shyh Chang, A.V. Segre, G. Shinoda, S.P. Shah, W.S. Einhorn, A. Takeuchi, J.M. Engreitz, J.P. Hagan, M.G. Kharas, A. Urbach, J.E. Thornton, R. Triboulet, R.I. Gregory, D. Altshuler, G.Q. Daley, The Lin28/let-7 axis regulates glucose metabolism, Cell 147 (2011) 81–94, <https://doi.org/10.1016/j.cell.2011.08.033>.
- [5] S. Dong, B. Yang, H. Guo, F. Kang, MicroRNAs regulate osteogenesis and chondrogenesis, Biochem. Biophys. Res. Commun. 418 (2012) 587–591, <https://doi.org/10.1016/j.bbrc.2012.01.075>.
- [6] X. Luo, C. Xu, J. Xiao, H. Shan, B. Yang, Z. Pan, H. Lin, W. Chu, Z. Wang, Y. Lu, The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes, J. Cell. Sci. 124 (2011) 3187, <https://doi.org/10.1242/jcs.010728>.
- [7] L. Lin, N. Li, D. Li, Q. Zhang, C. Wang, P. Wang, W. Tao, G. Ding, Z. Wang, P. Zhang, S.-M. Zhuang, W. Zhou, X. Cao, J. Hou, X. Liu, L. Zheng, MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma, J. Biol. Chem. 286 (2011) 36677–36685, <https://doi.org/10.1074/jbc.M111.270561>.
- [8] G. Zhu, L. Mei, H.D. Vishwasrao, O. Jacobson, Z. Wang, Y. Liu, B.C. Yung, X. Fu, A. Jin, G. Niu, Q. Wang, F. Zhang, H. Shroff, X. Chen, Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for

- cancer immunotherapy, *Nat. Commun.* 8 (2017) 1482, <https://doi.org/10.1038/s41467-017-01386-7>.
- [9] G. Yu, W. Yao, W. Xiao, H. Li, H. Xu, B. Lang, MicroRNA-34a functions as an anti-metastatic microRNA and suppresses angiogenesis in bladder cancer by directly targeting CD44, *J. Exp. Clin. Cancer Res.* 33 (2012), <https://doi.org/10.1186/s13046-014-0115-4>.
- [10] L. Tan, J.T. Yu, N. Hu, L. Tan, Non-coding RNAs in Alzheimer's disease, *Mol. Neurobiol.* 47 (2013) 382–393, <https://doi.org/10.1007/s12035-012-8359-5>.
- [11] M. Martins, A. Rosa, L.C. Guedes, B.V. Fonseca, K. Gotovac, S. Violante, T. Mestre, M. Coelho, M.M. RosaMá, E.R. Martin, J.M. Vance, T.F. Outeiro, L. Wang, F. Borovecki, J.J. Ferreira, S.A. Oliveira, Convergence of mirna expression profiling, α -synuclein interacton and GWAS in Parkinson's disease, *PLoS One* 6 (2011) e25443, <https://doi.org/10.1371/journal.pone.0025443>.
- [12] X. Ji, R. Takahashi, Y. Hiura, G. Hirokawa, Y. Fukushima, N. Iwai, Plasma miR-208 as a biomarker of myocardial injury, *Clin. Chem.* 55 (2009) 1944–1949, <https://doi.org/10.1373/clinchem.2009.125310>.
- [13] S. Dong, Y. Cheng, J. Yang, J. Li, X. Liu, X. Wang, D. Wang, T.J. Krall, E.S. Delphin, C. Zhang, MicroRNA expression signature and the role of MicroRNA-21 in the early phase of acute myocardial infarction, *J. Biol. Chem.* 284 (2009) 29514–29525, <https://doi.org/10.1074/jbc.M109.027896>.
- [14] E. Van Rooij, L.B. Sutherland, N. Liu, A.H. Williams, J. Mearns, R.D. Gerard, J.A. Richardson, E.N. Olson, A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure, *Proc. Natl. Acad. Sci. U. S. A.* 103 (2006) 18255–18260, <https://doi.org/10.1073/pnas.0608791103>.
- [15] D.A. Demirtas, A.O. Demirtas, A. Biskin, M.A. Demirtas, Micro-RNA in health and disease, *Int. J. Cardiol. Res.* 5 (2018) 116–123, <https://doi.org/10.19070/2470-4563-1800020>.
- [16] D. Quiat, E.N. Olson, MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment, *J. Clin. Invest.* 123 (2013) 11–18, <https://doi.org/10.1172/JCI62876>.
- [17] T.A. Farazi, J.I. Hoell, P. Morozov, T. Tuschl, MicroRNAs in human cancer, *Adv. Exp. Med. Biol.* 774 (2013) 1–20, https://doi.org/10.1007/978-94-007-5590-1_1.
- [18] J. Stanczyk, D.M. Leslie Pedrioli, F. Brentano, O. Sanchez-Pernaute, C. Kolling, R.E. Gay, M. Detmar, S. Gay, D. Kyburz, Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis, *Arthritis Rheum.* 58 (2008) 1001–1009, <https://doi.org/10.1002/art.23386>.
- [19] C. Ignacio, S.D. Hicks, P. Burke, L. Lewis, S. Szombathyne-Meszaros, F.A. Middleton, Alterations in serum microRNA in humans with alcohol use disorders impact cell proliferation and cell death pathways and predict structural and functional changes in brain, *BMC Neurosci.* 16 (2015) 55, <https://doi.org/10.1186/s12868-015-0195-x>.
- [20] D.C. Yu, Q.G. Li, X.W. Ding, Y.T. Ding, D.C. Yu, Q.G. Li, X.W. Ding, Y.T. Ding, Circulating microRNAs: potential biomarkers for cancer, *Int. J. Mol. Sci.* 12 (2011) 2055–2063, <https://doi.org/10.3390/ijms12032055>.
- [21] Y. Xie, T. Murray-Stewart, Y. Wang, F. Yu, J. Li, L.J. Marton, R.A.B. Casero, D. Oupický, Self-immolative nanoparticles for simultaneous delivery of microRNA and targeting of polyamine metabolism in combination cancer therapy, *J. Control. Release* 246 (2016) 110–119, <https://doi.org/10.1016/j.jconrel.2016.12.017>.
- [22] B. Santos-Carballal, L.J. Aaldering, M. Ritzfeld, S. Pereira, N. Sewald, B.M. Moerschbacher, M. Götte, F.M. Goycoolea, Physicochemical and biological characterization of chitosan-microRNA nanocomplexes for gene delivery to MCF-7 breast cancer cells, *Sci. Rep.* 5 (2015), <https://doi.org/10.1038/srep13567>.
- [23] F. Xu, J.Z. Liao, G.Y. Xiang, P.X. Zhao, F. Ye, Q. Zhao, X.X. He, MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma, *Cancer Med.* 6 (2017) 651–661, <https://doi.org/10.1002/cam4.1016>.
- [24] E. Blanco, H. Shen, M. Ferrari, Principles of nanoparticle design for overcoming biological barriers to drug delivery, *Nat. Biotechnol.* 33 (2015) 941–951, <https://doi.org/10.1038/nbt.3330>.
- [25] D. Baek, J. Villén, C. Shin, F.D. Camargo, S.P. Gygi, D.P. Bartel, The impact of microRNAs on protein output, *Nature* 455 (2008) 64–71, <https://doi.org/10.1038/nature07242>.
- [26] J.G. Doench, P.A. Sharp, Specificity of microRNA target selection in translational repression, *Genes Dev.* 18 (2004) 504–511, <https://doi.org/10.1101/gad.1184404>.
- [27] R.C. Lee, R.L. Feinbaum, V. Ambros, The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*, *Cell* 75 (1993) 843–854, [https://doi.org/10.1016/0092-8674\(93\)90529-Y](https://doi.org/10.1016/0092-8674(93)90529-Y).
- [28] B.P. Lewis, I.H. Shih, M.W. Jones-Rhoades, D.P. Bartel, Prediction of mammalian microRNA targets, *Cell* 115 (2003) 787–798, [https://doi.org/10.1016/S0092-8674\(03\)01018-3](https://doi.org/10.1016/S0092-8674(03)01018-3).
- [29] B.P. Lewis, C.B. Burge, D.P. Bartel, Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets, *Cell* 120 (2005) 15–20, <https://doi.org/10.1016/j.cell.2004.12.035>.
- [30] Y. Lee, K. Jeon, J.T. Lee, S. Kim, V.N. Kim, MicroRNA maturation: stepwise processing and subcellular localization, *EMBO J.* 21 (2002) 4663–4670, <https://doi.org/10.1093/emboj/cdf476>.
- [31] A.M. Denli, B.B.J. Tops, R.H.A. Plasterk, R.F. Ketting, G.J. Hannon, Processing of primary microRNAs by the microprocessor complex, *Nature* 432 (2004) 231–235, <https://doi.org/10.1038/nature03049>.
- [32] D.S. Schwarz, G. Hutvagner, T. Du, Z. Xu, N. Aronin, P.D. Zamore, Asymmetry in the assembly of the RNAi enzyme complex, *Cell* 115 (2003) 119–208, [https://doi.org/10.1016/S0092-8674\(03\)00759-1](https://doi.org/10.1016/S0092-8674(03)00759-1).
- [33] L.P. Lim, C.L. Lau, Nelson, P. Garrett-Engele, A. Grimson, J.M. Schelter, J. Castle, D.P. Bartel, P.S. Linsley, J.M. Johnson, Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs, *Nature* 433 (2005) 769–773, <https://doi.org/10.1038/nature03315>.
- [34] J.G. Doench, C.P. Petersen, P.A. Sharp, siRNAs can function as miRNAs, *Genes Dev.* 17 (2003) 438–442, <https://doi.org/10.1101/gad.1064703>.
- [35] S. Yekta, I.H. Shih, D.P. Bartel, MicroRNA-directed cleavage of HOXB8 mRNA, *Science* (80-) 304 (2004) 594–596, <https://doi.org/10.1126/science.1073827>.
- [36] M.A. Valencia-Sanchez, J. Liu, G.J. Hannon, R. Parker, Control of translation and mRNA degradation by miRNAs and siRNAs, *Genes Dev.* 20 (2006) 515–524, <https://doi.org/10.1101/gad.1399806>.
- [37] R.L. Montgomery, T.G. Hullinger, H.M. Semus, B.A. Dickinson, A.G. Seto, J.M. Lynch, C. Stack, P.A. Latimer, E.N. Olson, E. van Rooij, Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure, *Circulation* 124 (2011) 1537–1547, <https://doi.org/10.1161/CIRCULATIONAHA.111.030932>.
- [38] C.E. Grueter, E. Van Rooij, B.A. Johnson, S.M. DeLeon, L.B. Sutherland, X. Qi, L. Gautron, J.K. Elmquist, R. Bassel-Duby, E.N. Olson, A cardiac MicroRNA governs systemic energy homeostasis by regulation of MED13, *Cell* 149 (2012) 671–683, <https://doi.org/10.1016/j.cell.2012.03.029>.
- [39] P. Trang, J.F. Wiggins, C.L. Daigle, C. Cho, M. Omotola, D. Brown, J.B. Weidhaas, A.G. Bader, F.J. Slack, Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice, *Mol. Ther.* 19 (2011) 1116–1122, <https://doi.org/10.1038/mt.2011.48>.
- [40] A. Bouchie, First microRNA mimic enters clinic, *Nat. Biotechnol.* 31 (2013) 577, <https://doi.org/10.1038/nbt0713-577>.
- [41] Y. Chen, D.Y. Gao, L. Huang, In vivo delivery of miRNAs for cancer therapy: challenges and strategies, *Adv. Drug Deliv. Rev.* 81 (2015) 128–141, <https://doi.org/10.1016/j.addr.2014.05.009>.
- [42] D.M. Pereira, P.M. Rodrigues, P.M. Borralho, C.M.P. Rodrigues, Delivering the promise of miRNA cancer therapeutics, *Drug Discov. Today* 18 (2013) 282–289, <https://doi.org/10.1016/j.drudis.2012.10.002>.
- [43] G.D. Gray, S. Basu, E. Wickstrom, Transformed and immortalized cellular uptake of oligodeoxynucleoside phosphorothioates, 3'-alkylamino oligodeoxynucleotides, 2'-O-methyl oligoribonucleotides and oligodeoxynucleoside methylphosphonates, and peptide nucleic acids, *Biochem. Pharmacol.* 53 (1997) 1465–1476, [https://doi.org/10.1016/S0006-2952\(97\)82440-9](https://doi.org/10.1016/S0006-2952(97)82440-9).
- [44] S. van Dongen, C. Abreu-goodger, A.J. Enright, Detecting microRNA binding and siRNA off-target effects from expression data, *Nat. Methods* 5 (2008) 1023–1025, <https://doi.org/10.1038/nmeth.1267>.
- [45] A. Loinger, D.Y. Shemla, D.I. Simon, H. Margalit, O. Biham, Competition between small RNAs: a quantitative view, *Biophys. J.* 102 (2012) 1712–1721, <https://doi.org/10.1016/j.bpj.2012.01.058>.
- [46] B. Yu, X. Zhao, L.J. Lee, R.J. Lee, Targeted delivery systems for oligonucleotide therapeutics, *AAPS J.* 11 (2009) 195–203, <https://doi.org/10.1208/s12248-009-9096-1>.
- [47] R. Oberbauer, G.F. Schreiner, T.W. Meyer, Renal uptake of an 18-mer phosphorothioate oligonucleotide, *Kidney Int.* (1995) 1226–1232, <https://doi.org/10.1038/ki.1995.406>.
- [48] F. Czauderna, M. Fechtner, S. Dames, H. Aygün, A. Klippel, G.J. Pronk, K. Giese, J. Kaufmann, Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells, *Nucleic Acids Res.* 31 (2003) 2705–2716, <https://doi.org/10.1093/nar/gkg393>.
- [49] K. Raemdonck, R.E. Vandenbroucke, J. Demeester, N.N. Sanders, S.C. De Smedt, Maintaining the silence: reflections on long-term RNAi, *Drug Discov. Today* 13 (2008) 917–931, <https://doi.org/10.1016/j.drudis.2008.06.008>.
- [50] Y. Huang, M.S. Leisegang, G. Carmichael, H. Yong Jin, A. Gonzalez-Martin, A.V. Miletic, M. Lai, S. Knight, M. Sabouri-Ghomi, S.R. Head, M.S. Macauley, R.C. Rickert, C. Xiao, Transfection of microRNA mimics should be used with caution, *Front. Genet.* 6 (2015), <https://doi.org/10.3389/fgene.2015.00340>.
- [51] D.W. Thomson, C.P. Bracken, J.M. Szubert, G.J. Goodall, On measuring miRNAs after transient transfection of mimics or antisense inhibitors, *PLoS One* 8 (2013) 55214, <https://doi.org/10.1371/journal.pone.0055214>.
- [52] X. Zhang, X. He, Y. Liu, H. Zhang, H. Chen, S. Guo, Y. Liang, MiR-101-3p inhibits the growth and metastasis of non-small cell lung cancer through blocking PI3K/AKT signal pathway by targeting MALAT-1, *Biomed. Pharmacother.* 93 (2017) 1065–1073, <https://doi.org/10.1016/j.biopha.2017.07.005>.
- [53] T.M. Dang, W.C. Wong, S.M. Ong, P. Li, J. Lum, J. Chen, M. Poidinger, F. Zolezzi, S.C. Wong, MicroRNA expression profiling of human blood monocyte subsets highlights functional differences, *Immunology* 145 (2015) 404–416, <https://doi.org/10.1111/imm.12456>.
- [54] J. Visvanathan, S. Lee, B. Lee, J.W. Lee, S.K. Lee, The microRNA miR-124 antagonizes the anti-neural REST/SCP1 pathway during embryonic CNS development, *Genes Dev.* 21 (2007) 744–749, <https://doi.org/10.1101/gad.1519107>.
- [55] C. van Solingen, L. Seghers, R. Bijkerk, J.M. Duijs, M.K. Roeten, A.M. van Oeveren-Rietdijk, H.J. Baelde, M. Monge, J.B. Vos, H.C. de Boer, P.H. Quax, Antagonism-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis, *J. Cell. Mol. Med.* 13 (2009) 1577–1585, <https://doi.org/10.1111/j.1582-4934.2008.00613.x>.
- [56] X. Chen, S. Gu, B.F. Chen, W.L. Shen, Z. Yin, G.W. Xu, J.J. Hu, T. Zhu, G. Li, C. Wan, H.W. Ouyang, T.L. Lee, W.Y. Chan, Nanoparticle delivery of stable miR-199a-5p agomir improves the osteogenesis of human mesenchymal stem cells via the HIF1 α pathway, *Biomaterials* 53 (2015) 239–250, <https://doi.org/10.1016/j.biomaterials.2015.02.071>.
- [57] K.A. Lennox, M.A. Behlke, Chemical modification and design of anti-miRNA oligonucleotides, *Gene Ther.* 18 (2011) 1111–1120, <https://doi.org/10.1038/gt.2011.100>.
- [58] P. Velpurisiva, A. Gad, B. Piel, R. Jadia, P. Rai, Nanoparticle design strategies for effective cancer immunotherapy, *J. Biomed.* 2 (2017) 64–77, <https://doi.org/10.1038/s41467-017-01386-7>.

- 7150/jbm.18877.
- [59] C.V. Pecot, G.A. Calin, R.L. Coleman, G. Lopez-Berestein, A.K. Sood, RNA interference in the clinic: challenges and future directions, *Nat. Rev. Cancer* 11 (2011) 59–67, <https://doi.org/10.1038/nrc2966>.
 - [60] D. Cun, D.K. Jensen, M.J. Maltesen, M. Bunker, P. Whiteside, D. Scurr, C. Foged, H.M. Nielsen, D. Krohn, M. Jonas, M. Bunker, P. Whiteside, D. Scurr, C. Foged, H. Mørck, High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization, *Eur. J. Pharm. Biopharm.* 77 (2011) 26–35, <https://doi.org/10.1016/j.ejpb.2010.11.008>.
 - [61] P. Decuzzi, B. Godin, T. Tanaka, S.Y. Lee, C. Chiappini, X. Liu, M. Ferrari, Size and shape effects in the biodistribution of intravascularly injected particles, *J. Control. Release* 141 (2009) 320–327, <https://doi.org/10.1016/j.jconrel.2009.10.014>.
 - [62] S.H. Kim, H. Mok, J.H. Jeong, S.W. Kim, T.G. Park, Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate, *Bioconjug. Chem.* 17 (2006) 241–244, <https://doi.org/10.1021/bc050289f>.
 - [63] G. Liang, Y. Zhu, A. Jing, J. Wang, F. Hu, W. Feng, Z. Xiao, B. Chen, Cationic microRNA-delivering nanocarriers for efficient treatment of colon carcinoma in xenograft model, *Gene Ther.* 23 (2016) 829–838, <https://doi.org/10.1038/gt.2016.60>.
 - [64] T.J. Lee, J.Y. Yoo, D. Shu, H. Li, J. Zhang, J.G. Yu, A.C. Jaime-Ramirez, M. Acunzo, G. Romano, R. Cui, H.L. Sun, Z. Luo, M. Old, B. Kaur, P. Guo, C.M. Croce, RNA nanoparticle-based targeted therapy for glioblastoma through inhibition of oncogenic miR-21, *Mol. Ther.* 25 (2017) 1544–1555, <https://doi.org/10.1016/j.ymthe.2016.11.016>.
 - [65] G. Caracciolo, D. Caputo, D. Pozzi, V. Colapicchioni, R. Coppola, Size and charge of nanoparticles following incubation with human plasma of healthy and pancreatic cancer patients, *Colloids Surf. B Biointerfaces* 123 (2014) 673–678, <https://doi.org/10.1016/j.colsurfb.2014.10.008>.
 - [66] A. Parodi, C. Corbo, A. Cevenini, R. Molinaro, R. Palomba, L. Pandolfi, M. Agostini, F. Salvatore, E. Tasciotti, Enabling cytoplasmic delivery and organelle targeting by surface modification of nanocarriers, *Nanomedicine* 10 (2015) 1923–1940, <https://doi.org/10.2217/nmm.15.39>.
 - [67] L. Huang, S. Guo, Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy, *J. Nanomater.* 2011 (2011) 12, <https://doi.org/10.1155/2011/742895>.
 - [68] F. Barbero, L. Russo, M. Vitali, J. Piella, I. Salvo, M.L. Borrajo, M. Busquets-fité, R. Grandori, N.G. Bastús, E. Casals, Formation of the protein corona: the interface between nanoparticles and the immune system, *Semin. Immunol.* 34 (2017) 52–60, <https://doi.org/10.1016/j.smim.2017.10.001>.
 - [69] D. Nierenberg, A.R. Khaled, O. Flores, Formation of a protein corona influences the biological identity of nanomaterials, *Rep. Pract. Oncol. Radiother.* 23 (2018) 300–308, <https://doi.org/10.1016/j.rpor.2018.05.005>.
 - [70] R.R. Arvizo, O.R. Miranda, D.F. Moyano, C.A. Walden, K. Giri, R. Bhattacharya, J.D. Robertson, V.M. Rotello, J.M. Reid, P. Mukherjee, Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles, *PLoS One* 6 (2011) e24374, <https://doi.org/10.1371/journal.pone.0024374>.
 - [71] C. He, Y. Hu, L. Yin, C. Tang, C. Yin, Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles, *Biomaterials* 31 (2010) 3657–3666, <https://doi.org/10.1016/j.biomaterials.2010.01.065>.
 - [72] P. Aggarwal, J.B. Hall, C.B. McLeland, M.A. Dobrovolskaia, S.E. McNeil, Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy, *Adv. Drug Deliv. Rev.* 61 (2009) 428–437, <https://doi.org/10.1016/j.addr.2009.03.009>.
 - [73] A. Parodi, N. Quattrocchi, A.L. van de Ven, C. Chiappini, M. Evangelopoulos, J.O. Martinez, B.S. Brown, S.Z. Khaled, I.K. Yazdi, M.V. Enzo, L. Ienshart, M. Ferrari, E. Tasciotti, Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions, *Nat. Nanotechnol.* 8 (2013) 61–68, <https://doi.org/10.1038/nano.2012.212>.
 - [74] C.M.J. Hu, L. Zhang, S. Aryal, C. Cheung, R.H. Fang, L. Zhang, Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform, *Proc. Natl. Acad. Sci. U. S. A.* 108 (2011) 10980–10985, <https://doi.org/10.1073/pnas.1106634108>.
 - [75] D. Cosco, F. Cilurzo, J. Maiuolo, C. Federico, M.T. Di Martino, M.C. Cristiano, P. Tassone, M. Presta, D. Paolino, Delivery of miR-34a by chitosan/PLGA nanoparticles for the anticancer treatment of multiple myeloma, *Sci. Rep.* 5 (2015) 1–11, <https://doi.org/10.1038/srep17579>.
 - [76] C. Saraiva, D. Talhada, A. Rai, R. Ferreira, L. Ferreira, L. Bernardino, K. Ruscher, MicroRNA-124-loaded nanoparticles increase survival and neuronal differentiation of neural stem cells in vitro but do not contribute to stroke outcome in vivo, *PLoS One* 13 (2018) e0193609, <https://doi.org/10.1371/journal.pone.0193609>.
 - [77] C. Cai, Y. Xie, L. Wu, X. Chen, H. Liu, Y. Zhou, H. Zou, D. Liu, Y. Zhao, X. Kong, P. Liu, PLGA-based dual targeted nanoparticles enhance miRNA transfection efficiency in hepatic carcinoma, *Sci. Rep.* 7 (2017), <https://doi.org/10.1038/srep46250>.
 - [78] A. Ekin, O.F. Karatas, M. Culha, M. Ozen, Designing a gold nanoparticle-based nanocarrier for microRNA transfection into the prostate and breast cancer cells, *J. Gene Med.* 16 (2014) 331–335, <https://doi.org/10.1002/jgm.2810>.
 - [79] T. Zhang, X. Xue, D. He, J.T. Hsieh, A prostate cancer-targeted polyarginine-disulfide linked PEI nanocarrier for delivery of microRNA, *Cancer Lett.* 365 (2015) 156–165, <https://doi.org/10.1016/j.canlet.2015.05.003>.
 - [80] J. Du, L.A. Lane, S. Nie, Stimuli-responsive nanoparticles for targeting the tumor microenvironment, *J. Control. Release* 219 (2015) 205–214, <https://doi.org/10.1016/j.jconrel.2015.08.050>.
 - [81] J.P. Rao, K.E. Geckeler, Polymer nanoparticles: preparation techniques and size-control parameters, *Prog. Polym. Sci.* 36 (2011) 887–913, <https://doi.org/10.1016/j.progpolymsci.2011.01.001>.
 - [82] A. Lamprecht, N. Ubrich, M. Hombroire Pérez, C.M. Lehr, M. Hoffman, P. Maincent, Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique, *Int. J. Pharm.* 196 (2000) 177–182, [https://doi.org/10.1016/S0378-5173\(99\)00422-6](https://doi.org/10.1016/S0378-5173(99)00422-6).
 - [83] Y.S. Lee, P.J. Johnson, P.T. Robbins, R.H. Bridson, Production of nanoparticles-in-microparticles by a double emulsion method: a comprehensive study, *Eur. J. Pharm. Biopharm.* 83 (2013) 168–173, <https://doi.org/10.1016/j.ejpb.2012.10.016>.
 - [84] A. Mohamed, N.K. Kunda, K. Ross, G.A. Hutcheon, I.Y. Saleem, Polymeric nanoparticles for the delivery of miRNA to treat Chronic Obstructive Pulmonary Disease (COPD), *Eur. J. Pharm. Biopharm.* 136 (2019) 1–8, <https://doi.org/10.1016/j.ejpb.2019.01.002>.
 - [85] J. Yang, H. Liu, X. Zhang, Design, preparation and application of nucleic acid delivery carriers, *Biotechnol. Adv.* 32 (2014) 804–817, <https://doi.org/10.1016/j.biotechadv.2013.11.004>.
 - [86] A. Bhargava-Shah, K. Foygel, R. Devulapally, R. Paulmurugan, Orlistat and anti-sense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy, *Nanomedicine* 11 (2016) 235–247, <https://doi.org/10.2217/nmm.15.193>.
 - [87] X. Su, L. Kuang, C. Battle, T. Shaner, B.S. Mitchell, M.J. Fink, J. Jayawickramarajah, Mild two-step method to construct DNA-conjugated silicon nanoparticles: scaffolds for the detection of microRNA-21, *Bioconjugate* 25 (2014) 1739–1743, <https://doi.org/10.1021/bc5004026>.
 - [88] F. Degliangeli, P. Kshirsagar, V. Brunetti, P.P. Pompa, R. Fiammengio, Absolute and direct microRNA quantification using DNA–gold nanoparticle probes, *J. Am. Chem. Soc.* 136 (2014) 2264–2267, <https://doi.org/10.1021/ja412152x>.
 - [89] S.W. Yang, T. Vosch, Rapid detection of microRNA by a silver nanocluster DNA probe, *Anal. Chem.* 83 (2011) 6935–6939, <https://doi.org/10.1021/ac201903n>.
 - [90] H. Koo, S. Lee, J. Hee Na, S. Hwa Kim, S. Kwang Hahn, K. Choi, I. Chan Kwon, S. Young Jeong, K. Kim, Bioorthogonal copper-free click chemistry in vivo for tumor-targeted delivery of nanoparticles, *Angew. Chem. Int. Ed.* 124 (2012) 12006–12010, <https://doi.org/10.1002/ange.201206703>.
 - [91] L.E. Roode, H. Brighton, T. Bo, J.L. Perry, M.C. Parrott, F. Kersey, J.C. Luft, J.E. Bear, J.M. DeSimone, I.J. Davis, Subtomographic analysis of PRINT nanoparticle distribution reveals targeting variation based on cellular and particle properties, *Nanomed. Nanotechnol. Biol. Med.* 12 (2016) 1053–1062, <https://doi.org/10.1016/j.nano.2015.12.382>.
 - [92] M. Sambade, A. Deal, A. Schorzman, J.C. Luft, C. Bowerman, K. Chu, O. Karginova, A. Van Swearingen, W. Zamboni, J. DeSimone, C.K. Anders, Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT[®] nanoparticle formulation against non-small-cell lung cancer brain metastases, *Nanomedicine* 11 (2016) 1947–1955, <https://doi.org/10.2217/nmm-2016-0147>.
 - [93] B. Herranz-Blanco, E. Ginestar, H. Zhang, J. Hirvonen, H.A. Santos, Microfluidics platform for glass capillaries and its application in droplet and nanoparticle fabrication, *Int. J. Pharm.* 516 (2017) 100–105, <https://doi.org/10.1016/j.ijpharm.2016.11.024>.
 - [94] R. Karnik, F.X. Gu, S. Bose, P. Basto, C. Cannizzaro, R. Langer, O.C. Farokhzad, Microfluidic synthesis of polymeric nanoparticles, *ASME 2008 6th Int. Conf. Nanochannels, Microchannels, Minichannels* (2008) 1921–1922, <https://doi.org/10.1115/ICNMM2008-62218>.
 - [95] D. Chen, K.T. Love, Y. Chen, A.A. Eltoukhy, C. Kastrop, G. Sahay, A. Jeon, Y. Dong, K.A. Whitehead, D.G. Anderson, Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation, *J. Am. Chem. Soc.* 134 (2012) 6948–6951, <https://doi.org/10.1021/ja301621z>.
 - [96] N. Desai, Challenges in development of nanoparticle-based therapeutics, *AAPS J.* 14 (2012) 282–295, <https://doi.org/10.1208/s12248-012-9339-4>.
 - [97] D.F. Emerich, C.G. Thanos, The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis, *Biomol. Eng.* 23 (2006) 171–184, <https://doi.org/10.1016/j.bioeng.2006.05.026>.
 - [98] A.P. Griset, J. Walpole, R. Liu, A. Gaffey, Y.L. Colson, M.W. Grinstaff, Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system, *J. Am. Chem. Soc.* 131 (2009) 2469–2471, <https://doi.org/10.1021/ja807416t>.
 - [99] M. Ghorbani, H. Hamishehkar, N. Arsalani, A. Akbar, A novel dual-responsive core-crosslinked magnetic-gold nanogel for triggered drug release, *Mater. Sci. Eng. C* 68 (2016) 436–444, <https://doi.org/10.1016/j.msec.2016.06.007>.
 - [100] H.J. Lee, R. Namgung, W.J. Kim, J.I. Kim, I.K. Park, Targeted delivery of microRNA-145 to metastatic breast cancer by peptide conjugated branched PEI gene carrier, *Macromol. Res.* 21 (2013) 1201–1209, <https://doi.org/10.1007/s13233-013-1161-z>.
 - [101] A.F. Ibrahim, U. Weirauch, M. Thomas, A. Gruñeweller, R.K. Hartmann, A. Aigner, MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma, *Cancer Res.* 71 (2011) 5214–5224, <https://doi.org/10.1158/0008-5472.CAN-10-4645>.
 - [102] Q. Liu, R.T. Li, H.Q. Qian, J. Wei, L. Xie, J. Shen, M. Yang, X.P. Qian, L.X. Yu, X.Q. Jiang, B.R. Liu, Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles, *Biomaterials* 34 (2013) 7191–7203, <https://doi.org/10.1016/j.biomaterials.2013.06.004>.
 - [103] G.Y. Chiou, J.Y. Cherng, H.S. Hsu, M.L. Wang, C.M. Tsai, K.H. Lu, Y. Chien, S.C. Hung, Y.W. Chen, C.I. Wong, L.M. Tseng, P.I. Huang, C.C. Yu, W.H. Hsu, S.H. Chiou, Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial–mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma, *J. Control. Release* 159 (2012) 240–250, <https://doi.org/10.1016/j.jconrel.2012.01.014>.
 - [104] Y.P. Yang, Y. Chien, G.Y. Chiou, J.Y. Cherng, M.L. Wang, W.-L. Lo, Y.L. Chang,

- P.I. Huang, Y.W. Chen, Y.H. Shih, M.T. Chen, S.H. Chiou, Inhibition of cancer stem cell-like properties and reduced chemoresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI, *Biomaterials* 33 (2012) 1462–1476, <https://doi.org/10.1016/j.biomaterials.2011.10.071>.
- [105] S. Venkiteswaran, T. Thomas, T.J. Thomas, Selectivity of polyethylenimines on DNA nanoparticle preparation and gene transport, *ChemistrySelect* 1 (2016) 1144–1150, <https://doi.org/10.1002/slct.201600026>.
- [106] T. Bieber, H.-P. Elsässer, Preparation of a low molecular weight polyethylenimine for efficient cell transfection, *Biotechniques* 30 (2001) 74–81, <https://doi.org/10.2144/01301st03>.
- [107] C. Sun, T. Tang, H. Uludağ, J.E. Cuervo, Molecular dynamics simulations of DNA/PEI complexes: effect of PEI branching and protonation state, *Biophys. J.* 100 (2011) 2754–2763, <https://doi.org/10.1016/j.bpj.2011.04.045>.
- [108] S. Höbel, A. Aigner, Polyethylenimines for siRNA and miRNA delivery *in vivo*, *Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.* 5 (2013) 484–501, <https://doi.org/10.1002/wnan.1228>.
- [109] A.K. Varkouhi, M. Scholte, G. Storm, H.J. Haisma, Endosomal escape pathways for delivery of biologicals, *J. Control. Release* 151 (2011) 220–228, <https://doi.org/10.1016/j.jconrel.2010.11.004>.
- [110] J.V. Jokerst, T. Lobovkina, R.N. Zare, S.S. Gambhir, Nanoparticle PEGylation for imaging and therapy, *Nanomedicine (Lond.)* 6 (2011) 715–728, <https://doi.org/10.2217/nmm.11.19>.
- [111] F. Danhier, E. Ansorena, J.M. Silva, R. Coco, A. Le Breton, V. Préat, PLGA-based nanoparticles: an overview of biomedical applications, *J. Control. Release* 161 (2012) 505–522, <https://doi.org/10.1016/j.jconrel.2012.01.043>.
- [112] S.Y. Wong, J.M. Pelet, D. Putnam, Polymer systems for gene delivery—past, present, and future, *Prog. Polym. Sci.* 32 (2007) 799–837, <https://doi.org/10.1016/j.progpolymsci.2007.05.007>.
- [113] M.C. Serrano, R. Pagani, M. Vallet-Reg, J. Penã, I. Izquierdo, M.T. Portoles, *In vitro* biocompatibility assessment of poly (ϵ -caprolactone) films using L929 mouse fibroblasts, *Biomaterials* 25 (2004) 5603–5611, <https://doi.org/10.1016/j.biomaterials.2004.01.037>.
- [114] I. Grizzi, H. Garreau, S. Li, M. Vert, Hydrolytic degradation of devices based on poly (α -lactide acid) size-dependence, *Biomaterials* 16 (1995) 305–311, [https://doi.org/10.1016/0142-9612\(95\)93258-F](https://doi.org/10.1016/0142-9612(95)93258-F).
- [115] Y. Patil, J. Panyam, Polymeric nanoparticles for siRNA delivery and gene silencing, *Int. J. Pharm.* 367 (2009) 195–203, <https://doi.org/10.1016/j.ijpharm.2008.09.039>.
- [116] X. Yuan, B.A. Shah, N.K. Kotadia, J. Li, H. Gu, Z. Wu, The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery, *Pharm. Res.* 27 (2010) 1285–1295, <https://doi.org/10.1007/s11095-010-0103-0>.
- [117] S. Wang, J. Zhang, Y. Wang, M. Chen, Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy, *Nanomed. Nanotechnol. Biol. Med.* 12 (2016) 411–420, <https://doi.org/10.1016/j.nano.2015.09.014>.
- [118] P. Grossen, D. Witzigmann, S. Sieber, J. Huwyler, PEG-PCL-based nanomedicines: a biodegradable drug delivery system and its application, *J. Control. Release* 260 (2017) 46–60, <https://doi.org/10.1016/j.jconrel.2017.05.028>.
- [119] C. Mattu, R.M. Pabari, M. Boffito, S. Sartori, G. Ciardelli, Z. Ramtoola, Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells, *Eur. J. Pharm. Biopharm.* 85 (3) (2013) 463–472, <https://doi.org/10.1016/j.ejpb.2013.07.016>.
- [120] M. Prabakaran, J.F. Mano, Chitosan-based particles as controlled drug delivery systems, *Drug Deliv.* 12 (2004) 41–57, <https://doi.org/10.1080/10717540509889781>.
- [121] L. Hu, Y. Sun, Y. Wu, Advances in chitosan-based drug delivery vehicles, *Nanoscale* 5 (2013) 3103, <https://doi.org/10.1039/c3nr00338h>.
- [122] A. Bernkop-Schnürch, S. Dünhaupt, Chitosan-based drug delivery systems, *Eur. J. Pharm. Biopharm.* 81 (2012) 463–469, <https://doi.org/10.1016/j.ejpb.2012.04.007>.
- [123] D.F. Costa, V.P. Torchilin, Micelle-like nanoparticles as siRNA and miRNA carriers for cancer therapy, *Biomed. Microdev.* 20 (2018), <https://doi.org/10.1007/s10544-018-0298-0>.
- [124] L.M. Bravo-Anaya, K.G. Fernández-Solís, J. Rosselgong, J.L.E. Nano-Rodríguez, F. Carvajal, M. Rinaudo, Chitosan-DNA polyelectrolyte complex: influence of chitosan characteristics and mechanism of complex formation, *Int. J. Biol. Macromol.* 126 (2019) 1037–1049, <https://doi.org/10.1016/j.ijbiomac.2019.01.008>.
- [125] B. Layek, L. Lipp, J. Singh, Cell penetrating peptide conjugated chitosan for enhanced delivery of nucleic acid, *Int. J. Mol. Sci.* 16 (2015) 28912–28930, <https://doi.org/10.3390/ijms161226142>.
- [126] P. Nydert, A. Dragomir, L. Hjelte, Chitosan as a carrier for non-viral gene transfer in a cystic-fibrosis cell line, *Biotechnol. Appl. Biochem.* 51 (2008) 153–157, <https://doi.org/10.1042/BA20070197>.
- [127] D. Cosco, C. Federico, J. Maiuolo, S. Bulotta, R. Molinaro, D. Paolino, P. Tassone, M. Fresta, Physicochemical features and transfection properties of chitosan/polyoxamer 188/poly(α -lactide-co-glycolide) nanoplexes, *Int. J. Nanomed.* 9 (2014) 2359–2372, <https://doi.org/10.2147/IJN.S58362>.
- [128] T.A. Sonia, C.P. Sharma, Chitosan and its derivatives for drug delivery perspective, in: R. Jayakumar, R.A.A. Muzzarelli, M. Prabakaran (Eds.), *Chitosan Biomater. I*, Springer, Berlin, Heidelberg, 2011, pp. 23–53, https://doi.org/10.1007/12_2011_117.
- [129] B. Layek, J. Singh, *N*-Hexanoyl, *N*-octanoyl and *N*-decanoyl chitosans: Binding affinity, cell uptake, and transfection, *Carbohydr. Polym.* 89 (2012) 403–410, <https://doi.org/10.1016/j.carbpol.2012.03.021>.
- [130] S.Y. Chae, S. Son, M. Lee, M.K. Jang, J.W. Nah, Deoxycholic acid-conjugated chitosan oligosaccharide nanoparticles for efficient gene carrier, *J. Control. Release* 109 (2005) 330–344, <https://doi.org/10.1016/j.jconrel.2005.09.040>.
- [131] R. Mandke, J. Singh, Effect of acyl chain length and unsaturation on physico-chemical properties and transfection efficiency of *N*-acyl-substituted low-molecular-weight chitosan, *J. Pharm. Sci.* 101 (2012) 268–282, <https://doi.org/10.1002/jps.22767>.
- [132] K.T. Dicker, L.A. Gurski, S. Pradhan-Bhatt, R.L. Witt, M.C. Farach-Carson, X. Jia, Hyaluronan: a simple polysaccharide with diverse biological functions, *Acta Biomater.* 10 (2014) 1558–1570, <https://doi.org/10.1016/j.actbio.2013.12.019>.
- [133] A. Cadete, M.J. Alonso, Targeting cancer with hyaluronic acid-based nanocarriers: recent advances and translational perspectives, *Nanomedicine* 11 (2016) 2341–2357, <https://doi.org/10.2217/nmm-2016-0117>.
- [134] S. Ganesh, A.K. Iyer, D.V. Morrissey, M.M. Amiji, Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors, *Biomaterials* 34 (2013) 3489–3502, <https://doi.org/10.1016/j.biomaterials.2013.01.077>.
- [135] D. Landesman-Milo, M. Goldsmith, S.L. Ben-Arye, B. Witenberg, E. Brown, S. Leibovitch, S. Azriel, S. Tabak, V. Morad, D. Peer, Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells, *Cancer Lett.* 334 (2013) 221–227, <https://doi.org/10.1016/j.canlet.2012.08.024>.
- [136] X. Sun, N. Zhang, Cationic polymer optimization for efficient gene delivery, *Mini Rev. Med. Chem.* 10 (2010) 108–125.
- [137] Z.R. Cohen, S. Ramishetti, N. Peshes-Yaloz, M. Goldsmith, A. Wohl, Z. Zibly, D. Peer, Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles, *ACS Nano* 9 (2015) 1581–1591, <https://doi.org/10.1021/nn506248s>.
- [138] D. Haussecker, Current issues of RNAi therapeutics delivery and development, *J. Control. Release* 195 (2014) 49–54, <https://doi.org/10.1016/j.jconrel.2014.07.056>.
- [139] M.S. Lee, J.E. Lee, E. Byun, N.W. Kim, K. Lee, H. Lee, S.J. Sim, D.S. Lee, J.H. Jeong, Target-specific delivery of siRNA by stabilized calcium phosphate nanoparticles using dopa-hyaluronic acid conjugate, *J. Control. Release* 192 (2014) 122–130, <https://doi.org/10.1016/j.jconrel.2014.06.049>.
- [140] B.S. Sekhon, S.R. Kamboj, Inorganic nanomedicine-part 1, *Nanomed. Nanotechnol. Biol. Med.* 6 (2010) 516–522, <https://doi.org/10.1016/j.nano.2010.04.004>.
- [141] B.S. Sekhon, S.R. Kamboj, Inorganic nanomedicine-part 2, *Nanomed. Nanotechnol. Biol. Med.* 6 (2010) 612–618, <https://doi.org/10.1016/j.nano.2010.04.003>.
- [142] V. Mulens, M. del P. Morales, D.F. Barber, Development of magnetic nanoparticles for cancer gene therapy: a comprehensive review, *ISRN Nanomater.* 2013 (2013) 1–14, <https://doi.org/10.1155/2013/646284>.
- [143] A. Schade, E. Delyagina, D. Scharfenberg, A. Skorska, C. Lux, R. David, G. Steinhoff, Innovative strategy for microRNA delivery in human mesenchymal stem cells via magnetic nanoparticles, *Int. J. Mol. Sci.* 14 (2013) 10710–10726, <https://doi.org/10.3390/ijms140610710>.
- [144] P.T. Yin, B.P. Shah, K.B. Lee, Combined magnetic nanoparticle-based microRNA and hyperthermia therapy to enhance apoptosis in brain cancer cells, *Small* 10 (2014) 4106–4112, <https://doi.org/10.1002/smll.201400963>.
- [145] W. Cha, R. Fan, Y. Miao, Y. Zhou, C. Qin, X. Shan, X. Wan, J. Li, Mesoporous silica nanoparticles as carriers for intracellular delivery of nucleic acids and subsequent therapeutic applications, *Molecules* 22 (2017), <https://doi.org/10.3390/molecules22050782>.
- [146] A. Bertucci, E.A. Prasetyanto, D. Septiadi, A. Manicardi, E. Brognara, R. Gambari, R. Corradini, L. De Cola, Combined delivery of temozolomide and anti-miR221 PNA using mesoporous silica nanoparticles induces apoptosis in resistant glioma cells, *Small* 11 (2015) 5687–5695, <https://doi.org/10.1002/smll.201500540>.
- [147] A. Tivnan, W.S. Orr, V. Gubala, R. Nooney, D.E. Williams, C. McDonagh, S. Prenter, H. Harvey, R. Domingo-Fernández, I.M. Bray, O. Piskareva, C.Y. Ng, H.N. Lode, A.M. Davidoff, R.L. Stallings, Inhibition of neuroblastoma tumor growth by targeted delivery of MicroRNA-34a using anti-disialoganglioside GD2 coated nanoparticles, *PLoS One* 7 (2012) e38129, <https://doi.org/10.1371/journal.pone.0038129>.
- [148] M. Banik, T. Basu, Calcium phosphate nanoparticles: a study of their synthesis, characterization and mode of interaction with salmon testis DNA, *Dalton Trans.* 43 (2014) 3244–3259, <https://doi.org/10.1039/C3DT52522H>.
- [149] H. Jung, S.A. Kim, Y.G. Yang, H. Yoo, S.J. Lim, H. Mok, Long chain microRNA conjugates in calcium phosphate nanoparticles for efficient formulation and delivery, *Arch. Pharm. Res.* 38 (2015) 705–715, <https://doi.org/10.1007/s12272-014-0451-0>.
- [150] A.J. Mieszawska, W.J.M. Mulder, Z.A. Fayad, D.P. Cormode, Multifunctional gold nanoparticles for diagnosis and therapy of disease, *Mol. Pharm.* 10 (2013) 831–847, <https://doi.org/10.1021/mp3005885>.
- [151] E.E. Connor, J. Mwamuka, A. Gole, C.J. Murphy, M.D. Wyatt, Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity, *Small* 1 (2005) 325–327, <https://doi.org/10.1002/smll.200400093>.
- [152] P.K. Jain, K.S. Lee, I.H. El-Sayed, M.A. El-Sayed, Calculated absorption and scattering properties of gold nanoparticles of different size, shape, and composition: applications in biological imaging and biomedicine, *J. Phys. Chem. B* 110 (2006) 7238–7248, <https://doi.org/10.1021/jp057170o>.
- [153] R. Ghosh, L.C. Singh, J.M. Shohet, P.H. Gunaratne, A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells, *Biomaterials* 34 (2013) 807–816, <https://doi.org/10.1016/j.biomaterials.2012.10.023>.
- [154] P. Couvreur, G. Barret, Critical review in therapeutic drug carrier System, *J. Pediatr. Surg.* 5 (2005) 1–20, <https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v26.i6.10>.
- [155] Y. Zhao, L. Huang, Lipid nanoparticles for gene delivery, *Adv. Genet. Academic Press*, 2014, pp. 13–36, <https://doi.org/10.1016/B978-0-12-800148-6.00002-X>.

- [156] H. Lv, S. Zhang, B. Wang, S. Cui, J. Yan, Toxicity of cationic lipids and cationic polymers in gene delivery, *J. Control. Release* 114 (2006) 100–109, <https://doi.org/10.1016/j.jconrel.2006.04.014>.
- [157] X. Cheng, R.J. Lee, The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery, *Adv. Drug Deliv. Rev.* 99 (2016) 129–137, <https://doi.org/10.1016/j.addr.2016.01.022>.
- [158] S.H. Hsu, B. Yu, X. Wang, Y. Lu, C.R. Schmidt, R.J. Lee, L.J. Lee, S.T. Jacob, K. Ghoshal, Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor, *Nanomed. Nanotechnol. Biol. Med.* 9 (2013) 1169–1180, <https://doi.org/10.1016/j.nano.2013.05.007>.
- [159] T. Bejerano, S. Etzion, S. Elyagon, Y. Etzion, S. Cohen, Nanoparticle delivery of miRNA-21 mimic to cardiac macrophages improves myocardial remodeling after myocardial infarction, *Nano Lett.* 18 (2018) 5885–5891, <https://doi.org/10.1021/acs.nanolett.8b02578>.
- [160] Y.L. Zhou, Q.Q. Yang, Y.Y. Yan, C. Zhu, L. Zhang, J.B. Tang, Localized delivery of miRNAs targets cyclooxygenases and reduces flexor tendon adhesions, *Acta Biomater.* 70 (2018) 237–248, <https://doi.org/10.1016/j.actbio.2018.01.047>.
- [161] X. Zhang, Y. Li, Y.E. Chen, J. Chen, P.X. Ma, Cell-free 3D scaffold with two-stage delivery of miRNA-26a to regenerate critical-sized bone defects, *Nat. Commun.* 7 (2016) 1–15, <https://doi.org/10.1038/ncomms10376>.
- [162] J. Yang, M.E. Brown, H. Zhang, M. Martinez, Z. Zhao, S. Bhutani, S. Yin, D. Trac, J.J. Xi, M.E. Davis, High-throughput screening identifies microRNAs that target Nox2 and improve function after acute myocardial infarction, *Am. J. Physiol. Circ. Physiol.* 312 (2017) H1002–H1012, <https://doi.org/10.1152/ajpheart.00685.2016>.
- [163] F.M. Kouri, L.A. Hurley, W.L. Daniel, E.S. Day, Y. Hua, L. Hao, C.Y. Peng, T.J. Merkel, M.A. Queisser, C. Ritzer, H. Zhang, miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma, *Genes Dev.* 29 (2015) 732–745, <https://doi.org/10.1101/gad.257394.114>.
- [164] P.M. Costa, A.L. Cardoso, C. Custódia, P. Cunha, L. Pereira De Almeida, M.C. Pedrosa De Lima, miRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: a new multimodal gene therapy approach for glioblastoma, *J. Control. Release* 207 (2015) 31–39, <https://doi.org/10.1016/j.jconrel.2015.04.002>.
- [165] X. Cui, Y. Sun, M. Shen, K. Song, X. Yin, W. Di, Y. Duan, Enhanced chemotherapeutic efficacy of paclitaxel nanoparticles Co-delivered with MicroRNA-7 by inhibiting paclitaxel-induced EGFR/ERK pathway activation for ovarian cancer therapy, *ACS Appl. Mater. Interfaces* 10 (2018) 7821–7831, <https://doi.org/10.1021/acsami.7b19183>.
- [166] C. Paoletti, C. Divieto, V. Chiono, Impact of biomaterials on differentiation and reprogramming approaches for the generation of functional cardiomyocytes, *Cells* 7 (2018) 114, <https://doi.org/10.3390/cells7090114>.
- [167] L.L. Wang, Y. Liu, J.J. Chung, T. Wang, A.C. Gaffey, M. Lu, C.A. Cavanaugh, S. Zhou, R. Kanade, P. Atluri, E.E. Morrissey, J.A. Burdick, Sustained miRNA delivery from an injectable hydrogel promotes cardiomyocyte proliferation and functional regeneration after ischaemic injury, *Nat. Biomed. Eng.* 1 (2017) 983–992, <https://doi.org/10.1038/s41551-017-0157-y>.
- [168] T.M. Jayawardena, B. Egemazarov, E.A. Finch, L. Zhang, J.A. Payne, K. Pandya, Z. Zhang, P. Rosenberg, M. Mirosos, V.J. Dzau, MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes, *Circ. Res.* 110 (2012) 1465–1473, <https://doi.org/10.1161/CIRCRESAHA.112.269035>.
- [169] V. Di Mauro, M. Iafisco, N. Salvarani, M. Vacchiano, P. Carullo, G.B. Ramírez-Rodríguez, T. Patrício, A. Tampieri, M. Miragoli, D. Catalucci, Bioinspired negatively charged calcium phosphate nanocarriers for cardiac delivery of MicroRNAs, *Nanomedicine* 11 (2016) 891–906, <https://doi.org/10.2217/nnm.16.26>.
- [170] R.E. Barnett, D.J. Conklin, L. Ryan, R.C. Keskey, V. Ramjee, E.A. Sepulveda, S. Srivastava, A. Bhatnagar, W.G. Cheadle, Anti-inflammatory effects of miR-21 in the macrophage response to peritonitis, *J. Leukoc. Biol.* 99 (2) (2016) 361–371, <https://doi.org/10.1189/jlb.4a1014-489r>.
- [171] T. Nakasa, M. Yoshizuka, M. Andry Usman, E. Elbadry Mahmoud, M. Ochi, MicroRNAs and bone regeneration, *Curr. Genomics* 16 (2015) 441–452, <https://doi.org/10.2174/1389202916666150817213630>.
- [172] L. Zhao, J. Wu, M. Xu, W. Liu, J. Song, S. Yan, L. Gao, Y. Zhang, Induction of osteogenic differentiation of stem cells via a lyophilized microRNA reverse transfection formulation on a tissue culture plate, *Int. J. Nanomed.* 8 (2013) 1595, <https://doi.org/10.2147/IJN.S43244>.
- [173] Z. Wang, G. Wu, M. Wei, Q. Liu, J. Zhou, T. Qin, X. Feng, H. Liu, Z. Feng, Y. Zhao, Improving the osteogenesis of human bone marrow mesenchymal stem cell sheets by microRNA-21-loaded chitosan/hyaluronic acid nanoparticles via reverse transfection, *Int. J. Nanomed.* 11 (2016) 2091, <https://doi.org/10.2147/IJN.S104851>.
- [174] S. Oliveto, M. Mancino, N. Manfrini, S. Biffo, Role of microRNAs in translation regulation and cancer, *World J. Biol. Chem.* 8 (2017) 45, <https://doi.org/10.4331/wjbc.v8.i1.45>.
- [175] J. Conde, E.R. Edelman, N. Artzi, Target-responsive DNA/RNA nanomaterials for microRNA sensing and inhibition: The jack-of-all-trades in cancer nanotherapeutics? *Adv. Drug Deliv. Rev.* 81 (2015) 169–183, <https://doi.org/10.1016/j.addr.2014.09.003>.
- [176] Y.Y. Jin, J. Andrade, E. Wickstrom, Non-specific blocking of MIR-17-5p guide strand in triple negative breast cancer cells by amplifying passenger strand activity, *PLoS One* 10 (2015) 1–20, <https://doi.org/10.1371/journal.pone.0142574>.
- [177] L.J. Aaldering, H. Tayeb, S. Krishnan, S. Fletcher, S.D. Wilton, R.N. Veedu, Smart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapy, *RNA Biol.* 12 (2015) 412–425, <https://doi.org/10.1080/15476286.2015.1017234>.
- [178] N. Li, X. Zhao, L. Wang, S. Zhang, M. Cui, J. He, miR-494 suppresses tumor growth of epithelial ovarian carcinoma by targeting IGF1R, *Tumor Biol.* 37 (2016) 7767–7776, <https://doi.org/10.1007/s13277-015-4603-8>.
- [179] M. Binnewies, E.W. Roberts, K. Kersten, V. Chan, D.F. Fearon, M. Merad, L.M. Coussens, D.I. Gabrilovich, S. Ostrand-Rosenberg, C.C. Hedrick, R.H. Vonderheide, M.J. Pittet, R.K. Jain, W. Zou, T.K. Howcroft, E.C. Woodhouse, R.A. Weinberg, M.F. Krummel, Understanding the tumor immune microenvironment (TIME) for effective therapy, *Nat. Med.* 24 (2018) 541–550, <https://doi.org/10.1038/s41591-018-0014-x>.
- [180] K.C. Valkenburg, A.E. De Groot, K.J. Pienta, Targeting the tumour stroma to improve cancer therapy, *Nat. Rev. Clin. Oncol.* 15 (2018) 366–381, <https://doi.org/10.1038/s41571-018-0007-1>.
- [181] X. Deng, M. Cao, J. Zhang, K. Hu, Z. Yin, Z. Zhou, X. Xiao, Y. Yang, W. Sheng, Y. Wu, Y. Zeng, Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer, *Biomaterials* 35 (2014) 4333–4344, <https://doi.org/10.1016/j.biomaterials.2014.02.006>.
- [182] S. Xu, S.H. Nasr, D. Chen, X. Zhang, L. Sun, X. Huang, C. Qian, MiRNA extraction from cell-free biofluid using protein corona formed around carboxyl magnetic nanoparticles, *ACS Biomater. Sci. Eng.* 4 (2017) 654–662, <https://doi.org/10.1021/acsbiomaterials.7b00668>.
- [183] S.A. Agnihotri, N.N. Mallikarjuna, T.M. Aminabhavi, Recent advances on chitosan-based micro- and nanoparticles in drug delivery, *J. Control. Release* 100 (2004) 5–28, <https://doi.org/10.1016/J.JCONREL.2004.08.010>.
- [184] M. Trivedi, A. Singh, M. Talekar, G. Pawar, P. Shah, M. Amiji, MicroRNA-34a encapsulated in hyaluronic acid nanoparticles induces epigenetic changes with altered mitochondrial bioenergetics and apoptosis in non-small-cell lung cancer cells, *Sci. Rep.* 7 (2017) 1–17, <https://doi.org/10.1038/s41598-017-02816-8>.
- [185] L. Poliseno, P.P. Pandolfi, PTEN ceRNA networks in human cancer, *Methods* 77 (2015) 41–50, <https://doi.org/10.1016/j.jymeth.2015.01.013>.
- [186] L. Saadatpour, E. Fadaee, S. Fadaei, R.N. Mansour, M. Mohammadi, S.M. Mousavi, M. Goodarzi, J. Verdi, H. Mirzaei, Glioblastoma: exosome and microRNA as novel diagnosis biomarkers, *Cancer Gene Ther.* 23 (2016) 415, <https://doi.org/10.1038/cgt.2016.48>.
- [187] G. Wang, J.J. Wang, H.M. Tang, S.S.T. To, Targeting strategies on miRNA-21 and PDCD4 for glioblastoma, *Arch. Biochem. Biophys.* 580 (2015) 64–74, <https://doi.org/10.1016/j.abb.2015.07.001>.
- [188] Y. Yang, Cancer immunotherapy: harnessing the immune system to battle cancer, *J. Clin. Invest.* 125 (2015) 3335–3337, <https://doi.org/10.1172/JCI83871>.
- [189] J.B. Self-Fordham, A.R. Naqvi, J.R. Uttamani, V. Kulkarni, S. Nares, MicroRNA: dynamic regulators of macrophage polarization and plasticity, *Front. Immunol.* 8 (2017) 1–18, <https://doi.org/10.3389/fimmu.2017.01062>.
- [190] K. Essandoh, Y. Li, J. Huo, G.C. Fan, MiRNA-mediated macrophage polarization and its potential role in the regulation of inflammatory response, *Shock* 46 (2016) 122–131, <https://doi.org/10.1097/SHK.0000000000000604>.
- [191] Y. Ge, L. Zhang, M. Nikolova, B. Reva, E. Fuchs, Strand-specific in vivo screen of cancer-associated miRNAs unveils a role for miR-21 in SCC progression, *Nat. Cell Biol.* 18 (2015) 111–121, <https://doi.org/10.1038/ncb3275>.
- [192] A.J. Murphy, P.M. Guyre, P.A. Pioli, Estradiol suppresses NF- κ B activation through coordinated regulation of let-7a and miR-125b in primary human macrophages, *J. Immunol.* 184 (2010) 5029–5037, <https://doi.org/10.4049/jimmunol.0903463>.
- [193] K.D. Taganov, M.P. Boldin, K.J. Chang, D. Baltimore, NF- κ B-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses, *Proc. Natl. Acad. Sci. U. S. A.* 103 (2006) 12481–12486, <https://doi.org/10.1073/pnas.0605298103>.
- [194] C. Huang, X.J. Liu, QunZhou, J. Xie, T.T. Ma, X.M. Meng, J. Li, MiR-146a modulates macrophage polarization by inhibiting Notch1 pathway in RAW264.7 macrophages, *Int. Immunopharmacol.* 32 (2016) 46–54, <https://doi.org/10.1016/j.intimp.2016.01.009>.
- [195] A.A. Chaudhuri, A.Y.L. So, N. Sinha, W.S.J. Gibson, K.D. Taganov, R.M. O'Connell, D. Baltimore, Mir-125b potentiates macrophage activation, *J. Immunol.* 187 (2011) 5062–5068, <https://doi.org/10.4049/jimmunol.1102001>.
- [196] A.O. Meghna Talekar, Macrophage polarization and the effect of MicroRNA-155 administered in water-in-oil-in-water multiple emulsion formulations, *J. Clin. Cell. Immunol.* 6 (2) (2015) 1–7, <https://doi.org/10.4172/2155-9899.1000326>.
- [197] R.T. Martinez-Nunez, F. Louafi, T. Sanchez-Elsner, The interleukin 13 (IL-13) pathway in human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 receptor $\alpha 1$ (IL13R $\alpha 1$), *J. Biol. Chem.* 286 (2011) 1786–1794, <https://doi.org/10.1074/jbc.M110.169367>.
- [198] R.M. O'Connell, K.D. Taganov, M.P. Boldin, G. Cheng, D. Baltimore, MicroRNA-155 is induced during the macrophage inflammatory response, *Proc. Natl. Acad. Sci. U. S. A.* 104 (2007) 1604–1609, <https://doi.org/10.1073/pnas.0610731104>.
- [199] S.Y. Gun, S.W.L. Lee, J.L. Sieow, S.C. Wong, Targeting immune cells for cancer therapy, *Redox Biol.* (2019) 101174, <https://doi.org/10.1016/j.redox.2019.101174>.
- [200] K. Shao, S. Singha, X. Clemente-Casares, S. Tsai, Y. Yang, P. Santamaria, Nanoparticle-based immunotherapy for cancer, *J. Am. Chem. Soc.* 11 (2018) 40, <https://doi.org/10.1021/nn5062029>.
- [201] R.H. Fang, L. Zhang, Nanoparticle-based modulation of the immune system, *Annu. Rev. Chem. Biomol. Eng.* 7 (2016) 305–326, <https://doi.org/10.1146/annurev-chembioeng-080615-034446>.
- [202] J.M. Silva, E. Zupancic, G. Vandermeulen, V.G. Oliveira, A. Salgado, M. Videira, M. Gaspar, L. Graca, V. Pr  at, H.F. Florindo, In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces pro-phagocytic and therapeutic anti-tumor immune responses in a melanoma model, *J. Control. Release* 198 (2015) 91–103, <https://doi.org/10.1016/j.jconrel.2014.11.033>.
- [203] J.S. Dolina, S.S.J. Sung, T.I. Novobrantseva, T.M. Nguyen, Y.S. Hahn, Lipidoid nanoparticles containing PD-L1 siRNA delivered in vivo enter Kupffer cells and enhance NK and CD8 $^{+}$ T cell-mediated hepatic antiviral immunity, *Mol. Ther.* -

- Nucleic Acids 2 (2013) e72, <https://doi.org/10.1038/mtna.2012.63>.
- [204] M.B. Heo, Y.T. Lim, Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells, *Biomaterials* 35 (2014) 590–600, <https://doi.org/10.1016/j.biomaterials.2013.10.009>.
- [205] M.R. Choi, K.J. Stanton-maxey, J.K. Stanley, C.S. Levin, R. Bardhan, D. Akin, S. Badve, J. Sturgis, J.P. Robinson, R. Bashir, N.J. Halas, S.E. Clare, A cellular Trojan horse for delivery of therapeutic nanoparticles into tumors, *Nano Lett.* 7 (2007) 3759–3765, <https://doi.org/10.1021/nl072209h>.
- [206] M.R. Choi, R. Bardhan, K.J. Stanton-Maxey, S. Badve, H. Nakshatri, K.M. Stantz, N. Cao, N.J. Halas, S.E. Clare, Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse, *Cancer Nanotechnol.* 3 (2012) 47–54, <https://doi.org/10.1007/s12645-012-0029-9>.
- [207] A.C. Anselmo, J.B. Gilbert, S. Kumar, V. Gupta, R.E. Cohen, M.F. Rubner, S. Mitragotri, Monocyte-mediated delivery of polymeric backpacks to inflamed tissues: a generalized strategy to deliver drugs to treat inflammation, *J. Control. Release* 199 (2015) 29–36, <https://doi.org/10.1016/j.jconrel.2014.11.027>.
- [208] N. Doshi, A.J. Swiston, J.B. Gilbert, M.L. Alcaraz, R.E. Cohen, M.F. Rubner, S. Mitragotri, Cell-based drug delivery devices using phagocytosis-resistant backpacks, *Adv. Healthc. Mater.* 23 (2011) 105–109, <https://doi.org/10.1002/adma.201004074>.
- [209] Y. Song, C. Tang, C. Yin, Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells, *Biomaterials* 185 (2018) 117–132, <https://doi.org/10.1016/j.biomaterials.2018.09.017>.
- [210] U. Steinfeld, C. Pauli, N. Kaltz, C. Bergemann, H. Lee, T lymphocytes as potential therapeutic drug carrier for cancer treatment, *Int. J. Pharm.* 311 (2006) 229–236, <https://doi.org/10.1016/j.ijpharm.2005.12.040>.
- [211] O. Zupke, E. Distler, A. Jurchott, U. Paiphasiri, M. Dass, S. Thomas, F. Hartwig, M. Theobald, K. Landfester, V. Mailander, W. Herr, Nanoparticles and antigen-specific T-cell therapeutics: a comprehensive study on uptake and release, *Nanomedicine* 10 (2015) 1063–1076, <https://doi.org/10.2217/nnm.14.160> Sections View Article.
- [212] N. Siriwon, Y.J. Kim, E. Siegler, X. Chen, J.A. Rohrs, Y. Liu, P. Wang, CAR-T cells surface-engineered with drug-encapsulated nanoparticles can ameliorate intratumoral T-cell hypofunction, *Cancer Immunol. Res.* 6 (2018) 812–825, <https://doi.org/10.1158/2326-6066.CIR-17-0502>.
- [213] S.Y. Li, Y. Liu, C.F. Xu, S. Shen, R. Sun, X.J. Du, J.X. Xia, Y.H. Zhu, J. Wang, Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation, *J. Control. Release* 231 (2016) 17–28, <https://doi.org/10.1016/j.jconrel.2016.01.044>.
- [214] T.T. Smith, S.B. Stephan, H.F. Moffett, L.E. Mcknight, D. Reiman, E. Bonagofski, M.E. Wohlfahrt, S.P.S. Pillai, M.T. Stephan, In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers, *Nat. Nanotechnol.* 12 (2017) 813–820, <https://doi.org/10.1038/nnano.2017.57>.
- [215] S.A. Quezada, T.R. Simpson, K.S. Peggs, T. Merghoub, Jelena Vider, X. Fan, R. Blasberg, H. Yagita, P. Muranski, P.A. Antony, N.P. Restifo, J.P. Allison, Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts, *J. Exp. Med.* 207 (2010) 637–650, <https://doi.org/10.1084/jem.20091918>.
- [216] S. Warashina, T. Nakamura, Y. Sato, Y. Fujiwara, M. Hyodo, H. Hatakeyama, H. Harashima, A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells, *J. Control. Release* 225 (2016) 183–191, <https://doi.org/10.1016/j.jconrel.2016.01.042>.
- [217] L.M. Kranz, M. Diken, H. Haas, S. Kreiter, C. Loquai, K.C. Reuter, M. Meng, D. Fritz, F. Vascotto, H. Hefesha, C. Grunwits, M. Vormehr, Y. Husemann, A. Selmi, A.N. Kuhn, J. Buck, E. Derhovanessian, R. Rae, S. Attig, J. Diekmann, R.A. Jabulowsky, S. Heesch, J. Hassel, P. Langguth, S. Grabbe, C. Huber, Ö. Türeci, U. Sahin, Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy, *Nature* 534 (2016) 396–401, <https://doi.org/10.1038/nature18300>.
- [218] J. Bilen, N. Liu, N.M. Bonini, A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins, *Cell Cycle* 5 (2006) 2835–2838, <https://doi.org/10.4161/cc.5.24.3579>.
- [219] R. Johnson, W. Noble, G.G. Tagartaglia, N.J. Buckley, Neurodegeneration as an RNA disorder, *Prog. Neurobiol.* 99 (2012) 293–315, <https://doi.org/10.1016/j.pneurobio.2012.09.006>.
- [220] H.K. Karnati, M.K. Panigrahi, R.K. Gutti, N.H. Greig, I.A. Tamargo, miRNAs: key players in neurodegenerative disorders and epilepsy, *J. Alzheimers Dis.* 48 (2015) 563–580, <https://doi.org/10.3233/JAD-150395>.
- [221] E. Doxakis, Post-transcriptional regulation of α -synuclein expression by mir-7 and mir-153, *J. Biol. Chem.* 285 (2010) 12726–12734, <https://doi.org/10.1074/jbc.M109.086827>.
- [222] G. Wang, J.M. van der Walt, G. Mayhew, Y.J. Li, S. Züchner, W.K. Scott, E.R. Martin, J.M. Vance, Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of α -synuclein, *Am. J. Hum. Genet.* 82 (2008) 283–289, <https://doi.org/10.1016/j.ajhg.2007.09.021>.
- [223] E. Miñones-Moyano, S. Porta, G. Escaramis, R. Rabionet, S. Iraola, B. Kagerbauer, Y. Espinosa-Parrilla, I. Ferrer, X. Estivill, E. Martí, MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function, *Hum. Mol. Genet.* 20 (2011) 3067–3078, <https://doi.org/10.1093/hmg/ddr210>.
- [224] J. Kim, K. Inoue, J. Ishii, W.B. Vanti, S.V. Voronov, E. Murchison, G. Hannon, A. Abeliovich, A MicroRNA feedback circuit in midbrain dopamine neurons, *Science* (80-) 317 (2007) 1220–1224, <https://doi.org/10.1126/science.1140481>.
- [225] L. de Mena, E. Coto, L.F. Cardo, M. Díaz, M. Blázquez, R. Ribacoba, C. Salvador, P. Pastor, L. Samaranch, G. Moris, M. Menéndez, A.I. Corao, V. Alvarez, Analysis of the Micro-RNA-133 and PITX3 genes in Parkinson's disease, *Am. J. Med. Genet. Part B: Neuropsychiatr. Genet.* 153 (2010) 1234–1239, <https://doi.org/10.1002/ajmg.b.31086>.
- [226] V. Boissoneault, I. Plante, S. Rivest, P. Provost, MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1, *J. Biol. Chem.* 284 (2009) 1971–1981, <https://doi.org/10.1074/jbc.M807530200>.
- [227] H.C. Zhu, L.M. Wang, M. Wang, B. Song, S. Tan, J.F. Teng, D.X. Duan, MicroRNA-195 downregulates Alzheimer's disease amyloid- β production by targeting BACE1, *Brain Res. Bull.* 88 (2012) 596–601, <https://doi.org/10.1016/j.brainresbull.2012.05.018>.
- [228] S.S. Hébert, B. De Strooper, miRNAs in neurodegeneration, *Science* (80-) 317 (2007) 1179–1180, <https://doi.org/10.1126/science.1148530>.
- [229] W.X. Wang, B.W. Rajeev, A.J. Stromberg, N. Ren, G. Tang, Q. Huang, I. Rigoutsos, P.T. Nelson, The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of β -site amyloid precursor protein-cleaving enzyme 1, *J. Neurosci.* 28 (2008) 1213–1223, <https://doi.org/10.1523/JNEUROSCI.5065-07.2008>.
- [230] S.S. Hébert, B. De Strooper, Alterations of the microRNA network cause neurodegenerative disease, *Trends Neurosci.* 32 (2009) 199–206, <https://doi.org/10.1016/j.tins.2008.12.003>.
- [231] C. Delay, F. Calon, P. Mathews, S.S. Hébert, Alzheimer-specific variants in the 3'UTR of Amyloid precursor protein affect microRNA function, *Mol. Neurodegener.* 6 (2011) 70, <https://doi.org/10.1186/1750-1326-6-70>.
- [232] J. Yao, T. Hennessey, A. Flynt, E. Lai, M.F. Beal, M.T. Lin, MicroRNA-related cofilin abnormality in Alzheimer's disease, *PLoS One* 5 (2010) e15546, <https://doi.org/10.1371/journal.pone.0015546>.
- [233] H. Geekiyanaage, C. Chan, MicroRNA-137/181c regulates serine palmitoyl-transferase and in turn amyloid β , novel targets in Sporadic Alzheimer's disease, *J. Neurosci.* 31 (2011) 14820–14830, <https://doi.org/10.1523/jneurosci.3883-11.2011>.
- [234] P.Y. Smith, C. Delay, J. Girard, M.A. Papon, E. Planel, N. Sergeant, L. Buée, S.S. Hébert, MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy, *Hum. Mol. Genet.* 20 (2011) 4016–4024, <https://doi.org/10.1093/hmg/ddr330>.
- [235] H. Wang, A.L. Moyano, Z. Ma, Y. Deng, Y. Lin, C. Zhao, L. Zhang, M. Jiang, X. He, Z. Ma, F. Lu, M. Xin, W. Zhou, S.O. Yoon, E.R. Bongarzone, Q.R. Lu, miR-219 cooperates with miR-338 in myelination and promotes myelin repair in the CNS, *Dev. Cell* 40 (2017), <https://doi.org/10.1016/j.devcel.2017.03.001> 566–582.e5.
- [236] M. Sinha, J. Ghose, N.P. Bhattacharyya, Micro RNA -214,-150,-146a and-125b target Huntingtin gene, *RNA Biol.* 8 (2011) 1005–1021, <https://doi.org/10.4161/rna.8.6.16035>.
- [237] P. Colella, G. Ronzitti, F. Mingozzi, Emerging issues in AAV-mediated in vivo gene therapy, *Mol. Ther. - Methods Clin. Dev.* 8 (2018) 87–104, <https://doi.org/10.1016/j.omtm.2017.11.007>.
- [238] Y. Miyazaki, H. Adachi, M. Katsuno, M. Minamiyama, Y.M. Jiang, Z. Huang, H. Doi, S. Matsumoto, N. Kondo, M. Iida, G. Tohna, Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2, *Nat. Med.* 18 (2012) 1136, <https://doi.org/10.1038/nm.2791>.
- [239] M. Fukuoka, M. Takahashi, H. Fujita, T. Chiyo, H.A. Popiel, S. Watanabe, H. Furuya, M. Murata, K. Wada, T. Okada, Y. Nagai, H. Hohjoh, Supplemental treatment for Huntington's disease with miR-132 that is deficient in Huntington's disease brain, *Mol. Ther. - Nucleic Acids* 11 (2018) 79–90, <https://doi.org/10.1016/j.omtn.2018.01.007>.
- [240] J. Dobson, Remote control of cellular behaviour with magnetic nanoparticles, *Nat. Nanotechnol.* 3 (2008) 139, <https://doi.org/10.1038/nnano.2008.39>.
- [241] S. Dante, A. Petrelli, E.M. Petrini, R. Marotta, A. Maccione, A. Alabastri, A. Quarta, F. De Donato, T. Ravasenga, A. Sathya, R. Cingolani, R. Proietti Zaccaria, L. Berdoncini, A. Barberis, T. Pellegrino, Selective targeting of neurons with inorganic nanoparticles: revealing the crucial role of nanoparticle surface charge, *ACS Nano* 11 (2017) 6630–6640, <https://doi.org/10.1021/acsnano.7b00397>.
- [242] R. Walters, I.L. Medintz, J.B. Delehanty, M.H. Stewart, K. Susumu, A.L. Huston, P.E. Dawson, G. Dawson, The role of negative charge in the delivery of quantum dots to neurons, *ASN Neuro* 7 (2015), <https://doi.org/10.1177/1759091415592389> 1759091415592389.
- [243] P. Kumar, H. Wu, J.L. McBride, K.E. Jung, M.H. Kim, B.L. Davidson, S.K. Lee, P. Shankar, N. Manjunath, Transvascular delivery of small interfering RNA to the central nervous system, *Nature* 448 (2007) 39–43, <https://doi.org/10.1038/nature05901>.
- [244] E.J. Kwon, J. Lasien, B.E. Jacobson, I.-K. Park, P.J. Horner, S.H. Pun, Targeted nonviral delivery vehicles to neural progenitor cells in the mouse subventricular zone, *Biomaterials* 31 (2010) 2417–2424, <https://doi.org/10.1016/j.biomaterials.2009.11.086>.
- [245] A.M. Louw, M.K. Kolar, L.N. Novikova, P.J. Kingham, M. Wiberg, J. Kjems, L.N. Novikov, Chitosan polyplex mediated delivery of miRNA-124 reduces activation of microglial cells in vitro and in rat models of spinal cord injury, *Nanomed. Nanotechnol. Biol. Med.* 12 (2016) 643–653, <https://doi.org/10.1016/j.nano.2015.10.011>.